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Blood and lymphatic vessels form extensive networks throughout the body, 
which function in order to deliver oxygen and nutrients to the tissues, to remove 
extravasated fluid and to absorb dietary lipids. The formation of new blood and 
lymphatic vessels (termed angiogenesis and lymphangiogenesis) is critical during 
embryonic development and in the adult, and is regulated by multiple signaling 
pathways. Vascular Endothelial Growth Factors (VEGFs) and their receptors 
(VEGFRs), as well as the Notch signaling system, are key governors of blood and 
lymphatic endothelial cell fate, and regulate angiogenesis and lymphangiogenesis in 
health and disease. Despite the numerous recent advances in the field of vascular 
biology, many steps in the complex processes of angiogenesis and 
lymphangiogenesis remain unclear. In this study we investigated the role of 
VEGFR3 signaling in blood endothelial cells, tip cell specification, as well as the 
interplay of the receptor with the VEGFR2 and the Notch signaling pathways during 
angiogenesis. 
VEGFR3 is a tyrosine kinase receptor that is mainly expressed in lymphatic 
endothelial cells in the adult. We observed VEGFR3 expression in sprouts that guide 
the blood vascular endothelium in angiogenic conditions. VEGFR3 blockade with a 
monoclonal antibody displayed synergistic properties with simultaneous VEGFR2 
targeting in reducing angiogenesis and inhibiting tumor growth. Furthermore we 
found that Notch signaling suppresses VEGFR3 expression in endothelial cells, 
identifying VEGFR3 as a novel tip cell marker, which is normally repressed by 
Notch activation.  
In the next step we employed a combination of genetic and in vitro models to 
show that loss of VEGFR3 results in a hypervascular phenotype, accompanied by 
loss of Notch signaling. VEGFR3 could be stimulated by VEGFC and activate Notch 
in blood endothelial cells. Our results point towards a mechanism where VEGFC 
produced by macrophages at the vascular front acts via VEGFR3 to activate Notch 
and turn tip into stalk cells; thus promoting the formation of stable vascular loops. 
Furthermore we identified the transcription factor FOXC2 as the downstream target 
of the VEGFC/VEGFR3/Notch signaling cascade. These data reinforce the idea that 
VEGFR3 has two distinct signaling modalities, one ligand-dependent and one 
ligand-independent, and that different perturbations in VEGFR3 expression and 
function result in diverse vascular phenotypes.  
Subsequently we investigated the interplay of VEGFR2 and VEGFR3 in 
postnatal angiogenesis and lymphangiogenesis, using a genetic approach of 
conditional mutagenesis. Various combinations of genetic ablation of VEGFRs and 
pharmacological inhibition of Notch showed that VEGFR2 is irreplaceable during 
sprouting angiogenesis, also in endothelial cells with low Notch signaling, and that 
it acts upstream of VEGFR3 expression in angiogenic settings. On the other hand 
VEGFR3 suppressed VEGFR2 expression in a negative feedback loop. Finally we 
employed for the first time lymphatic endothelial specific deletion of VEGFRs in 
postnatal conditions and found no significant role for VEGFR2 in lymphatic vessel 
growth or remodeling, while VEGFR3 signaling was indispensable. 
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Our results unravel previously unknown roles for VEGFR3 in sprouting 
angiogenesis and provide new insight into the signaling cross-talk of the receptor 
with other important regulators of blood vessel development. Increasing our 
understanding of the molecular mechanisms underlying this process is crucial in 
order to comprehend the pathophysiology of angiogenesis-related diseases, 
characterized by excessive or insufficient blood vessel growth, and to promote the 







































The formation of new blood and lymphatic vessels, termed angiogenesis and 
lymphangiogenesis respectively, are essential processes for numerous physiological 
and pathological processes. During the past decades major advances have been 
made in the field of vascular biology, including the identification of multiple novel 
molecular players that regulate angiogenesis and lymphangiogenesis. Subsequently 
some of these regulators have been targeted successfully in preclinical studies and 
more recently in clinical settings.  
Vascular Endothelial Growth Factors (VEGFs) and their receptors (VEGFRs), 
as well as the Notch signaling system, are major regulators of endothelial cell fate, 
and their signaling is commonly distorted in a number of pathologies, including 
tumor growth. It is now becoming clear that these molecules interact on multiple 
levels to control blood vessel development and growth. Knowledge of these 
interactions is required for the therapeutic manipulation of the vascular system, in 
order to treat cancer and other angiogenesis-related diseases.  
In this study we investigated the role of VEGFR3 in blood vessel 
morphogenesis, plus the interplay of this receptor with the main regulator of 
angiogenesis, VEGFR2, as well as the versatile Notch signaling pathway. Our results, 
combined with other scientific contributions made over the past years, improve our 
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REVIEW OF THE LITERATURE 
 
1. ANATOMY AND FUNCTION OF THE VASCULAR SYSTEMS 
 
1.1 The blood vascular system 
All large multicellular organisms require a vascular system in order to supply 
oxygen and nutrients to tissues and to remove carbon dioxide and metabolic waste 
products. Vertebrates have a closed blood circulatory system, where the heart acts as 
a pump that circulates highly oxygenated blood to the body via the systemic 
circulation, and deoxygenated blood from the right side of the heart to the lungs, 
through the pulmonary circulation. All tissues are vascularized, with the exception 
of cartilage and the cornea. Blood vessels are lined by endothelial cells (ECs) and are 
hierarchically organized into arteries, arterioles, capillaries, venules and veins. 
Capillaries, which are 5-10 µm in diameter and connect arterioles with venules, 
represent the major site of exchange of water, gases, electrolytes, hormones, cells, 
nutrients and waste products between the blood end the interstitial fluid. 
 
1.1.1 Blood vessels structure and physiology 
In vertebrates, large blood vessels such as arteries, are composed in general 
from three layers; an interior layer composed of ECs (tunica intima), an intermediate 
layer composed of vascular smooth muscle cells (vSMCs), nerves and elastin (tunica 
media), and an external layer composed of collagen and fibroblasts (tunica externa). 
The composition of blood vessel wall varies, depending on the size and function of 
the vessel. For example capillaries consist only of a single layer of ECs, pericytes and 
basal lamina. As the diameter of the blood vessels increases, they become associated 
with SMCs (arteries, arterioles, veins). Furthermore many veins have valves, 
composed of two luminal leaflets of two layers of ECs separated by an extracellular 
matrix (ECM) core, that prevent blood backflow (Bazigou and Makinen 2013).  
The basement membrane (BM) is a sheet-like structure of 50–100 nm thickness, 
which lies basolateral to the endothelium (Vracko 1974). The main components of 
the BM are type IV collagen, laminin, heparan-sulphate proteoglycans (HSPGs) and 
nidogen/entactin. The exact composition of the BM varies depending on the tissue. 
These components have the unique capacity to self-assemble in order to form the BM, 
which provides structural support and regulates cell behavior. For example matrix 
metalloproteinases (MMPs) and integrins are key mediators of pro- and anti-
angiogenic behavior of the vascular endothelium, and different structural 
configuration of the components of the BM may have a direct impact on EC behavior 
during quiescent and angiogenic conditions (Kalluri 2003).  
 
1.1.1.1 Regulation of vascular permeability 
Endothelial cells form the inner lining of blood vessels and are important 
regulators of several functional, metabolic and synthetic functions. ECs are 
connected to each other with intercellular junctions, termed adheres junctions (AJs), 
and tight junctions (TJs), which are however not as strictly spatially organized as in 
epithelial cells (Bazzoni and Dejana 2004). These connections function to regulate 
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vascular permeability and integrity, as well as vascular homeostasis, by controlling 
the passage of substances between the intravascular and extravascular 
compartments. Vascular Endothelial Cadherin (VEC) is the most prominent cadherin 
at the AJs, and binds to and interacts with VEGFR2 (Shay-Salit, Shushy et al. 2002, 
Giannotta, Trani et al. 2013) and VE-PTP (Nawroth, Poell et al. 2002). Tight junctions 
are formed by occludin, claudins and JAM-A, as well as intracellular components 
like ZO proteins and actin cytoskeleton. 
The barrier function of the endothelium is not only regulated at the 
aforementioned paracellular level (between ECs), but also by transcellular pathways, 
where materials are transferred through ECs. The morphology of the vascular 
endothelium is not uniform throughout the vascular tree, and is classified into three 
different types: continuous, fenestrated and discontinuous. In continuous endothelia 
(for example in large arteries, lung vessels, heart, skeletal muscle, central nervous 
system and skin) ECs form an uninterrupted barrier between blood and tissues. 
Fenestrated endothelia occur in endocrine glands, intestinal tract, pancreas and 
kidney, where the ECs have round openings around 70 nm in diameter that allow 
the diffusion of fluids and small solutes. The fenestrae are spanned by thin (5-6 nm) 
nonmembranous diaphragms. Finally sinusoidal endothelia are a special type of 
fenestrated capillaries, with larger openings in the ECs (100-200 nm) and a 
discontinuous basement membrane that allows the transfer of cells and serum 
proteins across the basal lamina. Sinusoidal endothelia are found in liver, spleen and 
bone marrow (Aird 2007).  
 
1.1.1.2 Regulation of flow 
Blood vessels are covered with mural cells, a term that refers to vSMCs and 
pericytes. Single or multiple layers of vSMCs cover large arteries and veins, while 
capillaries are surrounded by pericytes that are embedded in the same basement 
membrane as the endothelium. Arterioles and venules are covered by mural cells 
with intermediate properties between typical vSMC and pericytes (Gerhardt and 
Betsholtz 2003). vSMCs support the large vessels and through their contractile 
properties regulate vasoconstriction and vasodilation, and subsequently blood flow 
and blood pressure. Pericytes are also contractile in vitro, in vivo and ex vivo and 
some studies suggest that they regulate blood flow at the capillary level (Peppiatt, 
Howarth et al. 2006, Yemisci, Gursoy-Ozdemir et al. 2009, Fernandez-Klett, 
Offenhauser et al. 2010). The distribution of pericytes in several capillary beds varies 
greatly throughout the body (Sims 1991) and the CNS vasculature is considered to 
be the most pericyte covered (Mathiisen, Lehre et al. 2010). In the brain, pericytes are 
part of the neurovascular unit (NVU), which also includes ECs, astrocyte endfeet, 
microglia and neurons. Pericytes play a major role in the formation of the blood-
brain-barrier (BBB) by regulating brain vessel permeability and endothelial 
transcytosis (Armulik, Genove et al. 2010, Daneman, Zhou et al. 2010).  
 
1.1.1.3 Organogenesis and tissue regeneration 
During embryo organogenesis the blood vasculature acts as a passive conduit 
of oxygen and nutrients. Moreover, the developing tissues experience inductive 
interactions from the ECs (Lammert, Cleaver et al. 2001, Matsumoto, Yoshitomi et al. 
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2001, Sakaguchi, Sadler et al. 2008). In the adult, numerous studies demonstrate the 
involvement of the vasculature in stem cell homeostasis and regeneration, and in 
tissue regeneration. Endothelial cells of individual organs have a unique and distinct 
phenotypic and functional signature (Ruoslahti and Rajotte 2000, Carmeliet 2005, 
Aird 2007, Aird 2007, Red-Horse, Crawford et al. 2007, Butler, Nolan et al. 2010, 
Nolan, Ginsberg et al. 2013), and through the production of tissue-specific paracrine 
trophogens, known as angiocrine factors, they support adult organ regeneration in 
lung (Ding, Nolan et al. 2011), liver (Ding, Nolan et al. 2010), and bone marrow 
(Butler, Nolan et al. 2010, Kobayashi, Butler et al. 2010). It has also been suggested 
that pericytes act as multipotent stem/progenitor cells, which may constitute 
mesenchymal stem cells (MSCs) (Davidoff, Middendorff et al. 2004, Crisan, Yap et al. 
2008, Feng, Mantesso et al. 2011), white adipocyte progenitor cells (Tang, Zeve et al. 
2008, Olson and Soriano 2011), muscle stem cells (Dellavalle, Sampaolesi et al. 2007), 
and neural stem cells (Dore-Duffy, Katychev et al. 2006). However, the lack of 
absolutely pericyte-specific markers has limited the fate mapping of these cells, 
raising the possibility that they derive from other perivascular progenitors (Armulik, 
Genove et al. 2011).  
 
1.2 The lymphatic vascular system 
The lymphatic vascular system is an unidirectional system that runs parallel 
to the blood vascular system and consists of lymphatic capillaries, precollecting and 
collecting lymphatic vessels. Due to the high blood pressure within the arteries, 
plasma and macromolecules filtrate continuously from the blood compartment into 
the interstitial space. About 90% of this protein rich fluid is reabsorbed by venous 
capillaries and post-capillary venules (Jeltsch, Tammela et al. 2003, Levick and 
Michel 2010). The main function of the lymphatic vasculature is to return the 
remaining extravasated fluid from the interstitial space into the blood circulation in 
an unidirectional fashion. Initially fluid, proteins, lipids, immune cells and large 
macromolecules (termed as lymph) enter blind–ended lymphatic capillaries that 
drain into precollecting and collecting lymphatic vessels. The lymph is returned to 
the venous circulation either through the thoracic duct at the left subclavian vein, or 
via the right lymphatic duct at the junction of the subclavian and internal jugular 
veins. The lymphatic vasculature permeates all vascularized tissues with the 
exception of CNS, retina, cornea, cartilage and bone marrow, although recently an 
analogous “glymphatic” system has been discovered to mediate waste clearance in 
the brain (Iliff, Wang et al. 2012). 
 
1.2.1 Lymphatic vessels structure and physiology 
Lymphatic capillaries are highly permeable, thin blind-ended vessels, 30-80 
µm of diameter. They are composed of oak-leaf-shaped lymphatic endothelial cells 
(LECs) sitting on a discontinuous BM. The capillary LECs have overlapping flaps 
that function as “microvalves” that prevent fluid escape into the interstitium 
(Trzewik, Mallipattu et al. 2001). The junctions between LECs in lymphatic 
capillaries are discontinuous or “button” like (Baluk, Fuxe et al. 2007), and are the 
sites of leucocyte entry into the lymphatic vessels. The lymphatic capillaries are 
attached to the ECM by elastic anchoring filaments that prevent the collapse of 
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capillaries due to increased interstitial pressure, and allow opening of their lumen in 
conditions of tissue swelling (Leak and Burke 1966, Leak and Burke 1968). After 
lymph is taken up from lymphatic capillaries, it is directed into contractile 
precollecting and collecting vessels that are covered by basement membrane and 
pericytes/SMCs. The collecting lymphatic vessels, specialized for lymph transport, 
have continuous “zipper” like junctions (Baluk, Fuxe et al. 2007) and they also 
contain luminal valves. The bileaflet lymphatic valves consist of two semilunar 
leaflets (Lauweryns and Boussauw 1973) that open and close depending on the fluid 
pressure within the lymphatic vessels in order to prevent retrogate lymph flow. The 
unidirectional lymph movement is regulated by the lymphatic valves, together with 
other intrinsic forces (like SMCs contractions) and extrinsic forces (like cardiac and 
arterial pulsation, skeletal muscle contractility and respiration) (Alitalo 2011).  
 
1.2.1.1 Main functions of the lymphatic system 
In addition to tissue fluid homeostasis, the lymphatic system is also 
responsible for the trafficking of antigen presenting cells (APCs) to regional lymph 
nodes, where they encounter and interact with lymphocytes; thus the lymphatic 
vessels form an important element of the immune system. Furthermore the lacteal 
lymphatic vessels in the villi of the small intestine are responsible for the absorption 
and transportation of dietary lipids (chylomicrons) that are released by intestinal 
enterocytes (Tammela and Alitalo 2010). Finally, lymphatic capillaries in the 
subcutaneous interstitial compartment may participate in blood pressure regulation 
during excess salt intake, via a VEGFC/VEGR3 dependent mechanism (Machnik, 
Neuhofer et al. 2009, Wiig, Schroder et al. 2013).  
 
 
2. BLOOD AND LYMPHATIC VESSEL DEVELOPMENT AND GROWTH 
 
2.1 Embryonic vessel development 
2.1.1 Vasculogenesis and angiogenesis 
The cardiovascular system is the first functional system than develops in 
vertebrates. The initial step in blood vessel formation is the differentiation of a 
subset of primitive mesodermal cells into endothelial cells (termed angioblasts). 
Angioblasts originate from the posterior primitive streak. They are positive for 
VEGFR2/Fetal liver kinase 1 (Flk1), the earliest marker of developing endothelial 
cells that can be detected already at embryonic day (E) 7.0 (Dumont, Fong et al. 1995). 
These precursors migrate to the yolk sac, where they form clusters of endothelial 
and hematopoietic progenitors, known as blood islands. The blood islands fuse and 
generate a primary capillary plexus. The assembly of vascular progenitors into the 
primitive plexus is termed vasculogenesis (Risau and Flamme 1995), while the 
formation of new blood vessels from preexisting ones, either by sprouting or by 
splitting (intussusception) is called angiogenesis (Risau 1997, Djonov, Schmid et al. 
2000, Burri, Hlushchuk et al. 2004). Different developing organs rely to different 
extent on vasculogenesis and angiogenesis for their vascularization, depending on 
whether they contain angioblasts (Ribatti, Vacca et al. 2001). !
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Following the formation of the primitive endothelium, the next step in blood 
vessel development is remodeling and maturation by endothelial cell proliferation, 
regression, migration and branching. Several factors orchestrate this complex 
process including genetic programming, growth and other modulating factors, 
mechanotransduction, blood flow and hypoxia (Coultas, Chawengsaksophak et al. 
2005). ECs are assigned arterial or venous identities (Wang, Chen et al. 1998, Adams, 
Wilkinson et al. 1999, Herzog, Guttmann-Raviv et al. 2005), establish their position 
along the body axis, and form new capillaries (Coultas, Chawengsaksophak et al. 
2005). VEGF and Notch signals are the key regulators of these early patterning 
events (Krebs, Xue et al. 2000, Lawson, Scheer et al. 2001, Hogan and Bautch 2004, 
Kearney, Kappas et al. 2004). Finally the new vessels become covered by pericytes 
and SMCs that provide strength and stability.!
 
2.1.2 Lymphangiogenesis  
The lymphatic system in the mouse starts to develop after the establishment 
of the blood circulation. LECs arise by differentiation from BECs in the cardinal vein 
(CV) at E9.0, at the time when the SRY-related HMG domain transcription factor 
SOX18 is expressed in ECs lining the dorsolateral area of the CV (Francois, Caprini et 
al. 2008). SOX18 cooperates with the orphan nuclear transcription factor COUP-TFII 
(Srinivasan, Geng et al. 2010) as a developmental switch, and activates the 
transcription of PROX1 as early as E9.5 (Wigle and Oliver 1999). At E10.5, PROX1 
positive LEC precursors bud from the dorsal side of the CV in a polarized manner 
and form the primitive lymph sacs, which can be found along the anteroposterior 
axis of the mouse embryo. Interestingly, a second source of LECs distinct from the 
CV, which is located at the lower edge of the superficial venous plexus, has been 
identified in mouse embryos (Hagerling, Pollmann et al. 2013). BECs in Prox1 null 
embryos fail to adopt a lymphatic cell phenotype and do not develop a lymphatic 
vasculature (Wigle, Harvey et al. 2002). LEC migration away from the CV is mainly 
orchestrated by VEGFC/VEGFR3 signaling (Karkkainen, Haiko et al. 2004). 
Following the formation of the primitive lymphatic capillary plexus, the 
peripheral lymphatic vessels form by sprouting lymphangiogenesis and mature into 
capillaries, pre-collecting and collecting vessels. Several molecules play essential 
roles in the maturation process, including the forkhead transcription factor FOXC2 
(Petrova, Karpanen et al. 2004), the nuclear factor of activated T cell (NFAT) c1 
transcription factor (Norrmen, Ivanov et al. 2009), EphrinB2 (Makinen, Adams et al. 
2005), the angiopoietins ANG1 and ANG2 (Gale, Thurston et al. 2002, Shimoda, 
Bernas et al. 2007, Dellinger, Hunter et al. 2008), and integrin a9 (Bazigou, Xie et al. 
2009). 
The venous origin of the lymphatic system, suggested by the medical scientist 
Florence Sabin already in 1902 (Sabin 1902), has been confirmed not only in mice, 
but also in zebrafish (Kuchler, Gjini et al. 2006, Yaniv, Isogai et al. 2006). Yet other 
models suggest that separate mesenchymal lymphangioblasts might contribute to 
the formation of the lymphatic vascular system in birds (Schneider, Othman-Hassan 
et al. 1999, Papoutsi, Tomarev et al. 2001, Wilting, Papoutsi et al. 2001, He, Papoutsi 
et al. 2003) and amphibians (Ny, Koch et al. 2005). To which extent these cells 
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contribute to murine embryonic lymphangiogenesis remains controversial (Buttler, 
Kreysing et al. 2006, Buttler, Ezaki et al. 2008, Bertozzi, Schmaier et al. 2010).  
 
2.1.3 Separation of the two vascular systems 
The separation of the lymphatic from the venous blood circulation depends 
largely on the interaction between the endothelial and hematopoietic systems. 
Failure of this separation results in blood filled lymphatic vessels and cutaneous 
hemorrhages. Several studies have shown that platelets mediate lymphatic/blood 
separation through activation of their receptor CLEC-2 by the transmembrane 
protein podoplanin, which is presented on LECs. Activation of CLEC-2 results in 
downstream activation of the tyrosine kinase SYK, the adaptor protein SLP-76, and 
PLCγ2 in platelets (Bertozzi, Hess et al. 2010). The exact mechanism of how platelet 
aggregation mediates separation of venous and lymphatic endothelial systems is 
thus far unknown, but it seems to involve a hemostatic blood clot (Hess, Rawnsley et 
al. 2014). 
 
2.2 Postnatal angiogenesis and lymphangiogenesis 
2.2.1 Postnatal angiogenesis  
2.2.1.1 Retinal angiogenesis and the “tip” vs. “stalk” cell concept 
Angiogenesis is mainly a developmental process, which continues during the 
early postnatal growth of tissues. One of the most studied blood vascular angiogenic 
beds is the rodent retina, which is immature and avascular at birth and becomes 
vascularized and fully mature during the first three weeks of life (Figure 1). The 
mouse retina is a powerful in vivo model for the study of vascular development in 
mice, because it becomes vascularized in a very tightly regulated and organized 
pattern (Fruttiger 2007), it is easily accessible, and allows reliable detection of any 
developmental abnormality (Stahl, Connor et al. 2010). Furthermore, it allows the 
analysis of various aspects of blood vessel growth at different stages of postnatal life, 
including EC sprouting, proliferation, remodeling and maturation (Pitulescu, 




Figure 1. Mouse retina at postnatal day 6. 
Whole mount immunohistochemistry for 
Isolectin B4 (iB4, in white). A: artery, V: 
Vein. Scalebar: 200 µm. 
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During sprouting angiogenesis, ECs acquire specialized phenotypes that 
contribute to the formation of new vascular networks in different ways. The “tip” 
cells are located at the forefront. Then extend filopodia towards the angiogenic 
stimulus, such as VEGF gradients. The tip cells lead the directional migration in 
order to invade the surrounding tissues, they are highly polarized and motile and do 
not proliferate. When the filopodia of adjacent tip cells meet, they connect and 
anastomose forming vascular loops (Herwig, Blum et al. 2011). Macrophages at the 
anastomosis sites are considered to release angiogenic factors and act as “bridges” 
between the tip cells (Fantin, Vieira et al. 2010). Just behind the tip cells follow the 
“stalk” cells that proliferate, remodel and form the vascular lumen (Gerhardt, 
Golding et al. 2003, Ruhrberg 2003). Further away from the angiogenic front, the 
quiescent lumenized endothelium consists of non-proliferating “phalanx” cells 
(Mazzone, Dettori et al. 2009). Tip, stalk and phalanx cells have different molecular 
signatures. For example, tip cells express high levels of VEGFR2 and platelet-derived 
growth factor (PDGF)-BB (Gerhardt, Golding et al. 2003), UNC5B (Lu, Le Noble et al. 
2004), DLL4 (Suchting, Freitas et al. 2007), neuropilin-1 (NP1) (Gerhardt, Ruhrberg et 
al. 2004), and MT1-MMP (Yana, Sagara et al. 2007), while stalk cells express VEGFR1 
(Krueger, Liu et al. 2011), Notch-regulated ankyrin repeat protein (NRARP) (Phng, 
Potente et al. 2009), Notch ligands Jagged1 and DLL1 (Roca and Adams 2007), 
ROBO4 (Jones, London et al. 2008), and VCAM1 (Harrington, Sainson et al. 2008, De 
Smet, Segura et al. 2009). Transcriptome analysis of ECs of DLL4+/- retinas, which 
are considered to contain an enriched tip cell population, and microarray analysis of 
retinal ECs isolated by laser capture microdissection, have shown that tip and stalk 
cells differ in the expression of several genes involved in ECM degradation, ECM 
proteins and transcription factors (del Toro, Prahst et al. 2010, Strasser, Kaminker et 
al. 2010). Furthermore, it has been suggested that the metabolic profile of ECs and 
the levels of glycolysis define EC behavior, and that overexpression of PFKFB3, a 
potent stimulator of glycolysis, promotes the formation of tip cells in some 
conditions (De Bock, Georgiadou et al. 2013, De Bock, Georgiadou et al. 2013). 
 
2.2.1.2 Angiogenesis in the adult 
Adult ECs are generally quiescent; with a turnover time of hundreds of days 
they are among the most genetically stable cells in the body (Folkman and D'Amore 
1996). Yet there are some processes that require angiogenic growth also in adulthood. 
These include neoangiogenesis in the female reproductive system, especially during 
corpus luteum formation in the ovary (Robinson 2013), during embryo implantation, 
and in the placenta during pregnancy (Zygmunt, Herr et al. 2003). Moreover 
angiogenesis in the adult occurs during fat mass expansion (Cao 2007), skeletal 
muscle hypertrophy in response to exercise (Gustafsson 2011), and wound healing 
(Tonnesen, Feng et al. 2000). Remarkably, ECs in the blood vessel wall may not all 
have the same angiogenic potential, since the endothelium contains a small 
population of CD117+ ECs with proliferative and clonogenic properties that could 
be the source of new ECs during cell maintenance and in angiogenic conditions 
(Fang, Wei et al. 2012). 
 
2.2.2 Postnatal lymphangiogenesis 
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During postnatal development lymphatic vessels grow, remodel, mature, 
alter their expression of LEC-specific markers and recruit SMCs (Dellinger, Hunter 
et al. 2008, Norrmen, Ivanov et al. 2009, Svingen, Francois et al. 2012). Interestingly, 
lymphatic vessels rely on VEGFR3 signaling only for the first two postnatal weeks in 
mice, and become resistant to VEGFR3 blockade thereafter (Karpanen, Wirzenius et 
al. 2006).  
In adults, physiological lymphangiogenesis happens during wound healing 
and acute inflammation (following for example bacterial infections) (Paavonen, 
Puolakkainen et al. 2000, Baluk, Tammela et al. 2005), during corpus luteum 
development (Brown and Russell 2014) and during pregnancy (Rutkowski, Ihm et al. 
2013). Lymphangiogenic sprouting is the principal mechanism of lymphatic vessel 
growth in adults (He, Rajantie et al. 2004, He, Rajantie et al. 2005), although some 
transdifferentiation of bone marrow derived cells into lymphatic vessels during 
inflammation has been shown in a cornea transplantation model (Religa, Cao et al. 
2005), after kidney transplantation (Kerjaschki, Huttary et al. 2006), in peritumoral 
and adult lymphangiogenesis (Zumsteg, Baeriswyl et al. 2009, Lee, Park et al. 2010), 
in human onchocerciasis (Attout, Hoerauf et al. 2009), and in idiopathic pulmonary 
fibrosis (El-Chemaly, Malide et al. 2009, El-Chemaly, Pacheco-Rodriguez et al. 2009). 
 
 
3. BLOOD AND LYMPHATIC VESSELS IN DISEASE 
 
3.1 Pathological angiogenesis 
3.1.1 Tumor angiogenesis  
The ability to sustain angiogenesis is an acquired capability of tumor cells and 
is considered one of the hallmarks of cancer progression (Hanahan and Weinberg 
2000, Hanahan and Weinberg 2011). Tumors alter their gene expression pattern to 
change the balance between angiogenesis inducers (like VEGF and FGF) and 
inhibitors (like thrombospondin-1, β-interferon and platelet factor-4) (Hanahan and 
Folkman 1996). In collaboration with environmental stimuli, such as 
metabolic/mechanical stress and immune responses, (Carmeliet and Jain 2000) the 
tumors activate the “angiogenic switch” (Folkman, Watson et al. 1989). Turning the 
switch “on” allows to dormant cancerous lesions to generate the required blood 
supply to grow beyond 1-2 mm in size and to metastasize. Most tumor 
vascularization occurs via sprouting angiogenesis and intussusception, however EC 
precursors mobilized from the bone marrow can be incorporated in the tumor blood 
vasculature as well, in a process termed postnatal vasculogenesis (Lyden, Hattori et 
al. 2001, Rafii, Meeus et al. 2002). Furthermore alternative types of nonangiogenic 
vascularization have been reporter in tumors, including vessel co-option (Donnem, 
Hu et al. 2013), vasculogenic mimicry (Maniotis, Folberg et al. 1999, Seftor, Hess et al. 
2012), EC generation from cancer stem-like cells (Wang, Chadalavada et al. 2010), 
and formation of mosaic vessels by incorporation of cancer cells to the vessel wall. 
The tumor vasculature is chaotic, consisting of irregularly shaped, tortuous and 
dilated blood vessels that demonstrate vascular shunting (Pries, Hopfner et al. 2010), 
show poorly connected or overlapping ECs (Hashizume, Baluk et al. 2000) that lack 
perivascular cells (Benjamin, Golijanin et al. 1999, Abramsson, Lindblom et al. 2003) 
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(Morikawa, Baluk et al. 2002), and have an abnormal BM (Baluk, Morikawa et al. 
2003). As a result tumor vasculature is heterogeneous, leaky and hemorrhagic, and 
the blood flow is irregular. 
 
3.1.2 Other angiogenesis-related diseases  
Excessive angiogenesis has been coupled together with chronic inflammation 
in several conditions, including rheumatoid arthritis, (Szekanecz, Besenyei et al. 
2010), osteoarthritis (Ashraf and Walsh 2008), psoriasis (Detmar, Brown et al. 1994), 
Crohn’s disease (Danese, Sans et al. 2006), ocular neovascularization (Miller, Adamis 
et al. 1994), obesity (Lemoine, Ledoux et al. 2013), and atherosclerotic plaque 
progression (Moreno, Purushothaman et al. 2006). Other vascular anomalies include 
benign vascular tumors (hemangiomas) and vascular malformations (Vikkula, Boon 
et al. 1998). The contribution of endothelial progenitor cells (EPCs) to the 
endothelium has been suggested in some of these conditions, but this mechanism 
remains still under debate (Bautch 2011). 
 
3.2 Lymphatic dysfunction 
3.2.1 Lymphedema  
The chronic accumulation of fluid in the interstitium results in disabling 
tissue swelling due to impaired drainage and is called lymphedema. The protein-
rich fluid triggers an inflammatory reaction that leads to fibrosis, accumulation of 
adipose tissue and impaired wound healing (Warren, Brorson et al. 2007). 
Lymphedema may be congenital or acquired. A number of somatic mutations 
account for the cases of inherited lymphedema. These include mutations in the 
intracellular tyrosine kinase domain of VEGFR3 resulting in inhibited 
autophosphorylation of the receptor (Milroy disease) (Ferrell, Levinson et al. 1998, 
Irrthum, Karkkainen et al. 2000, Karkkainen and Petrova 2000, Butler, Dagenais et al. 
2007, Ghalamkarpour, Holnthoner et al. 2009, Gordon, Spiden et al. 2013), 
nonsynonymous mutations in gap junction protein gamma-2 (GJC2) encoding 
connexin-47 (CX47) (“four limb lymphedema”) (Ferrell, Baty et al. 2010, Ostergaard, 
Simpson et al. 2011), insertions/deletions/nonsense mutations of the transcription 
factor FOXC2 leading to protein loss of function (LOF) (Lymphedema-Distichiasis) 
(Fang, Dagenais et al. 2000, van Steensel, Damstra et al. 2009), recessive or dominant 
mutations in SOX18 (hypotrichosis-lymphedema-telangiectasia syndrome) (Irrthum, 
Devriendt et al. 2003), homozygous or compound heterozygous mutations of CCBE1 
(collagen and calcium-binding EGF domain-1) (Hennekam syndrome) (Hennekam, 
Geerdink et al. 1989, Connell, Kalidas et al. 2010), mutations in the GATA-binding 
protein 2 (GATA2) (Emberger syndrome) (Hahn, Chong et al. 2011, Ostergaard, 
Simpson et al. 2011), hypomorphic mutations in the gene IKBKG that result in 
impaired NF-kappaB signaling (OL-EDA-ID syndrome) (Doffinger, Smahi et al. 
2001), as well as mutations in PTPN14 (protein tyrosine phosphatase, non-receptor 
type 14) (Au, Hernandez et al. 2010), in KIF11 (kinesin family member 11) 
(Ostergaard, Simpson et al. 2012), and VEGFC (Gordon, Schulte et al. 2013). Finally, 
the genetic cause underlying primary non-syndromic lymphedema (Meige disease) 
is so far unknown (Rezaie, Ghoroghchian et al. 2008). 
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Primary lymphedema is a rare disease, affecting 1.15/100,000 individuals 
under the age of 20 (Rockson and Rivera 2008). Most lymphedema cases are 
secondary. Infection with filaria worms affects currently 120 million people 
worldwide, of which approximately one third experience clinically overt 
lymphedema (Nutman 2013). In Western societies lymphedema usually follows 
surgical removal and/or irradiation of lymph nodes during cancer therapy. Breast 
cancer is a common case, with 21% of patients developing lymphedema in the arm 
post-operatively, and with higher rates correlating with axillary lymph node 
dissection compared to sentinel lymph node biopsy (DiSipio, Rye et al. 2013). 
Another cause of secondary lymphedema is inflammation of the lymphatic channels 
after infection of the skin with microorganisms (lymphangitis) (Rockson 2001).  
 
3.2.2 Tumor lymphangiogenesis and metastasis 
Lymphatic vessels may act as a getaway for lymphatic metastasis, which is 
suggested by many studies as the most common pathway for metastatic tumor 
spread (Leong 2011). Although intratumoral lymphatic vessels are dysfunctional due 
to high intratumoral pressure (Fukumura, Duda et al. 2010), peritumoral lymphatics 
correlate positively with lymph node and distal metastasis (Alitalo and Detmar 
2012). Lymphangiogenesis around the tumor and in the draining lymph nodes is 
triggered by overexpression of lymphangiogenic factors, such as VEGFC and 
VEGFD, which are produced by the tumors cells or by tumor associated 
macrophages (TAMs) (Tammela and Alitalo 2010). With mechanisms that are 
currently not well understood, tumor cells migrate and enter the lymphatic vessel 
lumen and are transferred to the sentinel lymph nodes by lymphatic flow. 
Subsequently tumor cells spread further away to distal lymph nodes and organs 
(Alitalo and Detmar 2012). 
 
3.2.3 Lymphatic vessels in other pathologies  Lymphangiogenesis is associated with the pathogenesis of diseases involving 
chronic inflammation, such as psoriasis (Kunstfeld, Hirakawa et al. 2004), 
rheumatoid arthritis (Zhang, Lu et al. 2007), idiopathic pulmonary fibrosis (El-
Chemaly, Malide et al. 2009), and Crohn’s disease (von der Weid, Rehal et al. 2011). 
Interestingly, tissue inflammation accompanying obesity, obesity associated 
metabolic disease and atherosclerosis, has been linked to lymphatic dysfunction, 
although the underlying molecular mechanisms are still poorly known (Alitalo 2011). 
The lymphatic vasculature can give rise to lymphovascular tumors, including benign 
lymphangiomas and malignant lymphangiosarcomas, the latter developing on the 
ground of chronic lymphedema (Morrison 2003), as well as Kaposi sarcoma, 
following infection with a gammaherpesvirus (KSHV) that reprograms BECs to 
LECs (Wang, Trotter et al. 2004). Finally, lymphatic vessels are involved in the 




4. MOLECULAR REGULATORS OF THE VASCULAR SYSTEMS 
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 The blood and lymphatic vasculature show a significant overlap in the 
expression of several molecular markers, signifying the close developmental, 
structural and functional relationship between those two systems. 
 
4.1 VEGFs and their receptors (VEGFRs) 
The VEGF family consists of VEGFA, VEGFB, VEGFC, VEGFD and placenta 
growth factor (PLGF) (Figure 2). Furthermore two non-mammalian homologues 
have been identified, the parapox virus open reading frame (VEGFE) (Ogawa, Oku 
et al. 1998, Meyer, Clauss et al. 1999) and the snake venom-derived polypeptides 
(VEGFF) (Yamazaki, Tokunaga et al. 2005). VEGFs are secreted glycoproteins 
containing a cystine knot motif (Iyer and Acharya 2011), consisting of antiparallel 
covalently linked homodimeric polypeptides; although heterodimers of VEGF and 
PLGF (DiSalvo, Bayne et al. 1995), as well as VEGF and VEGFB (Olofsson, Pajusola 
et al. 1996) have been described. VEGFRs belong to class V receptor tyrosine kinases 
(RTKs). They are composed of seven immunoglobulin  (Ig) extracellular domains, a 
transmembrane domain and a C-terminal intracellular kinase domain (Stuttfeld and 
Ballmer-Hofer 2009). Upon ligand binding the receptors undergo homo- and 
heterodimerization and auto- or transphosphorylation of tyrosine residues, resulting 
in the recruitment of intracellular signaling mediators with Src-homology-2 (SH2) or 
phosphotyrosine binding domains, and the activation of distinct downstream 
signaling pathways (Koch and Claesson-Welsh 2012). 
 
4.1.1 VEGF 
Originally described as “tumor vascular permeability factor” (Senger, Galli et 
al. 1983), VEGF was isolated and cloned in 1989 (Ferrara and Henzel 1989). Human 
VEGF exists in at least eight alternatively spliced isoforms (Takahashi and Shibuya 
2005). The most common forms, named VEGFA121, VEGFA165, VEGFA189 and 
VEGFA206, show different abilities to bind VEGFRs, heparate sulfate and NPs. For 
example VEGF121 lacks heparin-binding and is highly diffusible, while VEGF189 and 
VEGFA206 are highly basic and heparin-binding proteins that are tightly bound to the 
extracellular matrix; VEGF165 has intermediate properties (Houck, Ferrara et al. 1991). 
Although VEGF binds to VEGFR1 with an affinity that is 10-fold higher compared to 
VEGFR2 binding, VEGFR2 is the main VEGF signaling mediator in ECs (Takahashi 
and Shibuya 2005). Some VEGF isoforms also bind to VEGFR2 co-receptors NP1 
(Soker, Takashima et al. 1998) and NP2 (Gluzman-Poltorak, Cohen et al. 2000). 
VEGF is indispensable for embryonic development, and inactivation of a 
single VEGF allele results in death at mid-gestation (E11-E12) (Carmeliet, Ferreira et 
al. 1996, Ferrara, Carver-Moore et al. 1996). At the same time a modest increase in 
VEGF expression leads to severe heart developmental defects and embryonic death 
at E12.5 (Miquerol, Langille et al. 2000). Taken together these results highlight the 
importance of VEGF gene-dosage control during development. In the mouse embryo, 
VEGF is detected as early as at E7.0, and is later expressed in several organs and 
systems, including endocrine glands, kidney glomerulus, lymphoid aggregates, 
neural structures, the choroid plexus, bones and myocardium. VEGF expression sites 
are mainly juxtaposed to VEGFR2 expression (Dumont, Fong et al. 1995).   
 




Figure 2. VEGFRs, their co-receptors and their ligands. The main interactions between the ligands 
and receptors are shown. The dashed lines indicate the proteolytic processing required for VEGFC 
and VEGFD, which increases binding affinity towards VEGFR2 (Koch and Claesson-Welsh 2012, 
Jeltsch, Leppanen et al. 2013). 
 
In the adult, most cell types produce VEGF, including fibroblasts (Pertovaara, 
Kaipainen et al. 1994), hematopoietic stem cells (HSCs) (Bautz, Rafii et al. 2000), 
keratinocytes (Frank, Hübner et al. 1995), cardiac myofibroblasts (Chintalgattu, Nair 
et al. 2003), neuronal cells (Haigh, Gerber et al. 2000), macrophages (McLaren, 
Prentice et al. 1996), neutrophils (Taichman, Young et al. 1997), T cells (Freeman, 
Schneck et al. 1995), renal mesangial cells (Iijima, Yoshikawa et al. 1993) and 
endothelial cells (Namiki, Brogi et al. 1995). VEGF acts in a paracrine way, although 
an autocrine mode of action has been described for ECs and HSCs (Gerber, Malik et 
al. 2002, Lee, Chen et al. 2007). VEGF expression is controlled at transcriptional, post-
transcriptional and translational levels, by growth factors and cytokines, as well as 
by oncogenes like p53, Src, c-Myc, Fos and Bcl-2 (Xie, Wei et al. 2004). Hypoxia is a 
key stimulator of VEGF expression (Plate, Breier et al. 1992, Shweiki, Itin et al. 1992) 
and the VEGF mRNA transcription is induced in hypoxic microenvironments by 
hypoxia-inducible-factor (HIF-1) (Pugh and Ratcliffe 2003). 
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VEGF acts mainly on ECs, promoting their survival through the 
phosphatidylinositol (PI)-3 kinase−Akt pathway and the expression of Bcl-2 and A1, 
and their growth (Ferrara, Gerber et al. 2003). Furthermore, VEGF induces vascular 
permeability (Dvorak, Brown et al. 1995) and is associated with the development of 
fenestrations in ECs (Roberts and Palade 1995, Esser, Wolburg et al. 1998). 
Consequently adenoviral administration or transgenic overexpression of VEGF 
results in robust angiogenic effects in several tissues, and this is accompanied by 
vascular leakage and inflammation (Detmar, Brown et al. 1998, Larcher, Murillas et 
al. 1998, Thurston 2002, Baluk, Tammela et al. 2005). Although VEGF is needed for 
the postnatal survival and growth, the dependence on VEGF signaling is gradually 
lost as mice mature and reach adulthood (Gerber, Hillan et al. 1999). In addition 
VEGF signaling is important also in some non-endothelial cell types; for example it 
promotes survival, growth and migration of neural cells in the CNS and peripheral 
nervous system (PNS) (Zachary 2005, Rosenstein, Krum et al. 2010, Ruiz de 
Almodovar, Fabre et al. 2011), plays a critical role in fetal lung maturation by 
stimulating the production of surfactant proteins by type two pneumonocytes 
(Compernolle, Brusselmans et al. 2002), boosts bone formation by directly 
stimulating osteoblast differentiation, migration and growth (Midy and Plouet 1994, 
Mayr-Wohlfart, Waltenberger et al. 2002, Hiltunen, Ruuskanen et al. 2003), as well as 
chondrocyte development and survival (Maes, Stockmans et al. 2004). Finally it has 
multiple regulatory effects on bone-marrow derived cells (Ferrara, Gerber et al. 2003). 
VEGF is expressed in solid tumors by cancer cells, ECs and infiltrating TAMs, and 
plays a central role in the expansion of the tumor vascular bed and the growth of 
solid tumors (Kim, Li et al. 1993, Claesson-Welsh and Welsh 2013).  
 
4.1.2 VEGFB and PLGF 
 VEGFB (Olofsson, Pajusola et al. 1996) and PLGF (Maglione, Guerriero et al. 
1991) both function as ligands for VEGFR1 (Park, Chen et al. 1994, Olofsson, 
Korpelainen et al. 1998) and NP1 (Migdal, Huppertz et al. 1998, Makinen, Olofsson 
et al. 1999). VEGFB occurs in two alternative spliced isoforms in humans and mice 
(VEGFB167 and VEGFB168) (Olofsson, Pajusola et al. 1996). PLGF is made as four 
alternatively spliced isoforms with different heparin binding properties in humans, 
and as one isoform in mice (De Falco 2012). In the developing embryo, VEGFB can 
be detected already at E8.5, and is most prominent in the heart and skeletal muscle, 
as well as bones and cartilage (Aase, Lymboussaki et al. 1999); yet VEGFB gene 
deleted mice are viable without major abnormalities (Aase, von Euler et al. 2001). In 
adults, VEGFB localizes mainly in heart, skeletal muscle, brown fat and pancreas 
(Nash, Baca et al. 2006). On the other hand, PLGF is mainly expressed in the placenta 
throughout gestation (Achen, Gad et al. 1997, Vuorela, Hatva et al. 1997), but also in 
other tissues (De Falco 2012). Similarly to VEGFB, PLGF is not essential for 
embryonic development (Carmeliet, Moons et al. 2001). 
 Despite binding to the same receptors, VEGFB and PLGF have different 
biological activities. A possible explanation for these differences could lie in the 
unique structure of loop 1 of VEGFB compared to PLGF, and its inability to interact 
with the Ig homology domain 3 of VEGFR1 (Anisimov, Leppanen et al. 2013). 
VEGFB is a poor angiogenic inducer (Bhardwaj, Roy et al. 2003, Rissanen, 
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Markkanen et al. 2003, Karpanen, Bry et al. 2008). One strain of VEGFB-/- mice 
exhibits decreased heart size (Bellomo, Headrick et al. 2000), and VEGFB 
overexpression has been shown to promote cardiac hypertrophy with concurrent 
coronary growth and ischemia resistance, stemming from metabolic shifting to 
macromolecular synthesis and glucose oxidation (Karpanen, Bry et al. 2008, Bry, 
Kivela et al. 2010, Kivela, Bry et al. 2014). Furthermore VEGFB has been claimed to 
increase fatty acid transport in organs with high metabolic rate, such as the heart, by 
regulating the transcription of fatty acid transport proteins (Hagberg, Falkevall et al. 
2010). On the other hand, PLGF is proangiogenic (Ziche, Morbidelli et al. 1997, 
Odorisio, Schietroma et al. 2002), but mainly in pathological settings, such as 
ischemia, inflammation and wound healing (Carmeliet, Moons et al. 2001, Luttun, 
Tjwa et al. 2002, Pipp, Heil et al. 2003, Rakic, Lambert et al. 2003). At the same time 
the inhibition of PLGF in several disease conditions improved the associated 
pathological status (De Falco 2012). Finally although VEGFB expression can be 
detected in several tumor types, little is known about its significance in tumor 
progression (Fischer, Mazzone et al. 2008, Albrecht, Kopfstein et al. 2010); also the 
role or PLGF remains still controversial (Fischer, Jonckx et al. 2007, Bais, Wu et al. 
2010, Van de Veire, Stalmans et al. 2010).  
 
4.1.3 VEGFC and VEGFD 
VEGFC and VEGFD are produced as precursor proteins that can bind to and 
activate only VEGFR3 (Joukov, Pajusola et al. 1996, Lee, Gray et al. 1996). Both 
human proteins are cleaved by furin or the proprotein convertases PC5 and PC7 
(McColl, Baldwin et al. 2003, Siegfried, Basak et al. 2003, McColl, Paavonen et al. 
2007). This processing increases the binding affinity to VEGFR3. In addition, VEGFC 
is further proteolyticaly cleaved at the N-terminus into a 21 kDA popypeptide, 
which represents the mature form of the protein (∆N∆C) which is able to activate 
also VEGFR2 (Joukov, Pajusola et al. 1996). Yet, although the human fully processed 
VEGFD (∆N∆C) is able to bind to and activate VEGFR2 (Joukov, Sorsa et al. 1997, 
Achen, Jeltsch et al. 1998, Stacker, Stenvers et al. 1999), mouse VEGFD is not capable 
of binding to mouse VEGFR2 (Baldwin, Roufail et al. 2001). 
 
4.1.3.1 VEGFC 
VEGFC was the first ligand for VEGFR3 to be discovered (Joukov, Pajusola et 
al. 1996). It exists in three mRNA splice variants in humans (Lee, Gray et al. 1996) 
and two in mice. The shortest mRNA forms are rare and little is known about their 
biological activity. VEGFC is required for embryonic lymphatic vascular 
development. In VEGFC null mice, LECs remain trapped into the venous 
vasculature and fail to sprout from the CV; as a result the embryos do not develop a 
lymphatic vasculature and die at E15.5-17.5 (Karkkainen, Haiko et al. 2004, 
Hagerling, Pollmann et al. 2013). Mice mutant for the Collagen- and calcium-binding 
EGF domains 1 protein (CCBE1) phenocopy the VEGFC full knockout embryos. 
CCBE1 does not have any lymphangiogenic properties of its own, and it seems to act 
as a critical permissive modulator of VEGFC in lymphangiogenesis by enhancing the 
N-terminus cleavage of pro-VEGFC into mature VEGFC, by the metalloprotease 
ADAMTS3 (Bos, Caunt et al. 2011, Jeltsch, Jha et al. 2014, Le Guen, Karpanen et al. 
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2014). Although VEGFC+/- mice are viable, they show signs of lymphatic 
dysfunction, including chylous ascites, hypoplastic cutaneous lymphatic vessels and 
paw edema (Karkkainen, Haiko et al. 2004). In zebrafish VEGFC signaling is also 
indispensable for lymphatic system development (Kuchler, Gjini et al. 2006). 
During development, VEGFC is produced starting at E8.5 by mesenchymal 
cells in the perimetanephric, axillary and jugular regions, proximal to the areas 
where lymphatic vessels sprout (Kukk, Lymboussaki et al. 1996, Karkkainen, Haiko 
et al. 2004). In adults VEGFC is expressed close to the areas of VEGFR3 expression, 
suggesting a paracrine mode of action in LECs (Kukk, Lymboussaki et al. 1996, 
Lymboussaki, Olofsson et al. 1999). VEGFC is also present in platelets (Wartiovaara, 
Salven et al. 1998), and produced by BECs in the developing zebrafish ISVs, where it 
has been proposed to function in a cell autonomous manner to support BEC 
migration and angiogenesis (Villefranc, Nicoli et al. 2013). VEGFC produced in the 
murine brain, induces the proliferation of VEGFR3+ neural progenitors in the 
olfactory bulb and oligodentrocyte precursor cells in the optic nerve (Le Bras, 
Barallobre et al. 2006), and supports survival of dopaminergic neurons (Piltonen, 
Planken et al. 2011). In the zebrafish, VEGFC is produced by the dorsal aorta (DA) 
and activates VEGFR3 to promote and guide axon growth of motoneurons (Kwon, 
Fukuhara et al. 2013). Several sites of VEGFC production have also been described in 
humans (Partanen, Arola et al. 2000). 
VEGFC signaling via VEGFR3 is critical for LEC growth, survival and 
migration, via PKC dependent activation of p42/p44 MAPK, and PI3 kinase 
dependent Akt phosphorylation (Makinen, Veikkola et al. 2001). As a result, VEGFC 
is strongly lymphangiogenic. It induces sprouting lymphangiogenesis when 
overexpressed in the skin of transgenic mice (Jeltsch, Kaipainen et al. 1997) or with 
the use of viral vectors in the skin and mouse airways (Enholm, Karpanen et al. 2001, 
Saaristo, Veikkola et al. 2002, Baluk, Tammela et al. 2005), and when applied in the 
avian chorioallantoic membrane (CAM) (Oh, Jeltsch et al. 1997). VEGFC mediates 
lymphangiogenesis also in tumors, and its expression is associated with lymphatic 
metastasis to sentinel nodes and distal locations (Valtola, Salven et al. 1999, 
Karpanen, Egeblad et al. 2001, Mandriota, Jussila et al. 2001, Skobe, Hawighorst et al. 
2001a, Mattila, Ruohola et al. 2002, Hirakawa, Brown et al. 2007). On the other hand, 
VEGFC is angiogenic when overexpressed in transgenic mouse embryos before 
E16.5 (Lohela, Helotera et al. 2008), in the adult mouse cornea and in the CAM assay 
(Cao, Linden et al. 1998), in the myocardium after myocardial ischemia (Patila, 
Ikonen et al. 2006), and in skeletal muscle (Anisimov, Alitalo et al. 2009). VEGFC is 




VEGFD was discovered in 1996 as a c-fos-induced growth factor (FIGF) 
(Orlandini, Marconcini et al. 1996), and identified in 1998 as a novel ligand for 
VEGFR2 and VEGFR3 (Achen, Jeltsch et al. 1998). Alternative splicing in exon 6 
produces two distinct VEGFD isoforms (VEGF-D358 and VEGF-D326) with different C-
termini (Baldwin, Roufail et al. 2001). 
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In the mouse embryo VEGFD is detected starting at E7.5 and is expressed in 
several tissues (Avantaggiato, Orlandini et al. 1998). VEGFD deficient mice develop 
normally and do not show signs of lymphatic abnormality, apart from a minor 
reduction in the number of lymphatic vessels in the lungs (Baldwin, Halford et al. 
2005). In zebrafish, VEGFD has been implied in normal embryonic angiogenesis, as 
overexpression of VEGFD results in abnormal connections between the DA and the 
caudal vein, and truncated intersomitic vessels (ISVs) (Song, Yang et al. 2007). 
Furthermore it has been shown that VEGFD modulates SOX18 activity via the MEK-
ERK pathway, in order to determine arteriovenous differentiation in zebrafish, and 
early vascular development (starting at E11.5) in mouse embryos (Duong, Koltowska 
et al. 2014). In human adult tissues VEGFD is expressed mostly in the lung, heart, 
skeletal muscle, colon, and small intestine (Achen, Jeltsch et al. 1998). 
 VEGFD is a lymphangiogenic factor, and transgenic overexpression of 
VEGFD in the basal cells of the epidermis under the K14 promoter, or adenoviral 
delivery of VEGFD, induce lymphatic hyperplasia in mouse skin (Veikkola, Jussila et 
al. 2001, Byzova, Goldman et al. 2002). Adenoviral delivery of VEGFD produces 
lymphatic hyperplasia also in the airway epithelium of mice (Baluk, Tammela et al. 
2005). VEGFD is upregulated in many tumors and promotes lymphangiogenesis and 
lymphatic metastasis in mouse models and human cancers (Achen, Williams et al. 
2002, Von Marschall, Scholz et al. 2005, Kopfstein, Veikkola et al. 2007). VEGFD is 
able to produce angiogenic responses when administered via adenoviruses in rabbit 
hindlimb skeletal muscle and carotid arteries (Bhardwaj, Roy et al. 2003, Rissanen, 
Markkanen et al. 2003), porcine heart (Rutanen, Rissanen et al. 2004), and mouse 




 Initially known as Fms-like-TK-1 (Flt-1), VEGFR1, discovered in 1990 
(Shibuya, Yamaguchi et al. 1990), was shown to be a receptor for VEGF shortly 
thereafter (de Vries, Escobedo et al. 1992). VEGFR1 is a 180 kDA transmembrane 
glycoprotein that binds VEGF, VEGFB and PLGF. Although binding VEGF with an 
affinity that is an order of magnitude larger that VEGFR2 (Sawano, Takahashi et al. 
1996), the kinase activity of VEGFR1 is ten times lower that VEGFR2, suggesting that 
VEGFR1 acts as a “decoy” receptor during angiogenesis. Indeed VEGFR1-/- mice 
die at E8.5-9, due to excessive EC growth (Fong, Rossant et al. 1995), while 
conditional global deletion of VEGFR1 leads to increased angiogenesis in postnatal 
and adult mice, due to increased VEGFR2 protein accumulation and activation (Ho, 
Duan et al. 2012). Further supporting this function for VEGFR1, mice lacking the 
tyrosine kinase domain of the receptor (Flt1 TK-/-) develop normally (Hiratsuka, 
Minowa et al. 1998). Thus, a major function of VEGFR1 is to restrict VEGFR2 activity 
and signaling, also in a spatial local manner (Kappas, Zeng et al. 2008). 
VEGFR1 exists both as a full length receptor and as an alternative spliced 
soluble shorter variant (sFlt1) (Kendall and Thomas 1993). sFlt1 acts as a VEGF trap 
and contributes to corneal avascularity (Ambati, Patterson et al. 2007). Furthermore, 
during angiogenesis in the retina sFlt1 is required for EC sprout guidance (Chappell, 
Taylor et al. 2009). sFlt1 is produced by trophoblast cells in the placenta and has 
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been implicated in the pathogenesis of preeclampsia (Koga, Osuga et al. 2003, 
Maynard, Min et al. 2003, Levine, Maynard et al. 2004). In podocytes and 
perivascular cells in the kidney sFlt1 supports the integrity of the glomerular barrier 
(Jin, Sison et al. 2012). Interestingly, both VEGFR1 and sVEGFR1 are able to form 
heterodimers with VEGFR2 (Kendall, Wang et al. 1996, Huang, Andersson et al. 
2001), altering the signal transduction properties of the receptors. 
In the developing embryo, VEGFR1 is expressed already at E7.5 in the yolk 
sac mesoderm and around E9.5 it starts to be expressed also in the capillaries of the 
developing organs (Breier, Clauss et al. 1995). In adults, VEGFR1 is expressed in ECs 
(Peters, De Vries et al. 1993), but also in many non-endothelial cells, such as myeloid 
hematopoietic cells (monocytes and macrophages) (Barleon, Sozzani et al. 1996, 
Clauss, Weich et al. 1996), where it mediates VEGF induced chemotaxis (Hiratsuka, 
Minowa et al. 1998, Lyden, Hattori et al. 2001). This well documented function of 
VEGFR1 on monocyte migration is associated with inflammatory conditions, such as 
rheumatoid arthritis (Murakami, Iwai et al. 2006), and tumor associated 
inflammation (Schwartz, Rowinsky et al. 2010) and growth (Muramatsu, Yamamoto 
et al. 2010). VEGFR1 is required for bone marrow formation (Niida, Kondo et al. 
2005), megakaryocytic precursors maturation (Casella, Feccia et al. 2003), and has 
been implicated the establishment of the pre-metastatic niche in tumor models 
(Kaplan, Riba et al. 2005). VEGFR1 is able to promote angiogenesis via the 
expression of other growth factors by recruited macrophages (Kerber, Reiss et al. 
2008, Murakami, Zheng et al. 2008). Furthermore VEGFR1 expression in neuronal 
cells exerts several protective effects in different disease models (Li, Zhang et al. 2008, 
Poesen, Lambrechts et al. 2008, Falk, Zhang et al. 2009, Wittko, Schanzer et al. 2009, 
Dhondt, Peeraer et al. 2011). 
 
4.1.5 VEGFR2  
 VEGFR2, a transmembrane glycoprotein of 200 kDA, is the main VEGF 
receptor in ECs. It is also known as fetal liver kinase-1 (Flk1) in mice, and kinase-
insert domain receptor (KDR) in humans (Koch and Claesson-Welsh 2012). VEGFR2 
binds VEGF (Quinn, Peters et al. 1993), as well as the fully processed forms of 
VEGFC (∆N∆C) and human VEGFD (∆N∆C) (Joukov, Sorsa et al. 1997, Achen, 
Jeltsch et al. 1998, Stacker, Stenvers et al. 1999). The viral VEGFE (Ogawa, Oku et al. 
1998, Meyer, Clauss et al. 1999) and the snake venom VEGFF (Yamazaki, Tokunaga 
et al. 2005) are also specific ligands for VEGFR2. VEGFR2 is the main effector of 
VEGF signaling, regulating EC differentiation, survival, proliferation, migration, 
vascular permeability and vessel dilation (Koch and Claesson-Welsh 2012). 
Interestingly recent reports have suggested ligand-independent activation of 
VEGFR2, by reactive oxygen species (ROS) (Warren, Ziyad et al. 2014).  
 VEGFR2 exist as one isoform, however a soluble form of the receptor has been 
detected in human and mouse plasma (sVEGFR2) (Ebos, Bocci et al. 2004). The 
biological significance of this form is as yet unknown. 
 VEGFR2 is expressed early during development (E7.0) in extraembryonic and 
embryonic mesoderm and trophoblasts (Millauer, Wizigmann-Voos et al. 1993, 
Dumont, Fong et al. 1995). VEGFR2 is highly expressed in embryonic ECs during 
gestation and is required for the migration of mesodermal precursors of 
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hematopoietic and endothelial cells to the extraembryonic region of the embryo, 
where they further differentiate from a common precursor (termed 
“hemangioblast”) and make blood islands. Embryos deficient for VEGFR2 die at 
E8.5-9.5 due to developmental defects in vasculogenesis and hematopoiesis (Dumont, 
Fong et al. 1995, Shalaby, Rossant et al. 1995, Shalaby, Ho et al. 1997). VEGFR2 
becomes downregulated in ECs as the vasculature matures, but low-level autocrine 
VEGF/VEGFR2 signaling remains essential for EC homeostasis (Matsumoto and 
Claesson-Welsh 2001, Lee, Chen et al. 2007). Apart from the the ECs, VEGFR2 is also 
expressed in hematopoietic cells (Larsson-Blomberg and Dzierzak 1994, Katoh, 
Tauchi et al. 1995), hematopoietic stem cells (Ziegler, Valtieri et al. 1999), platelets 
(Selheim, Holmsen et al. 2002), as well as neurons in the CNS and PNS, where it 
plays a supportive/neuroprotective role (Zachary 2005). VEGFR2 expression in 
LECs can drive enlargement of lymphatic vessels after VEGF or VEGFE stimulation 
(Hong, Lange-Asschenfeldt et al. 2004, Wirzenius, Tammela et al. 2007). However it 
is not known whether such effects are secondary to changes in the blood vascular 
compartment, or recruitment of monocytes expressing VEGFC (Cursiefen, Chen et al. 
2004, Baluk, Tammela et al. 2005). Yet, lymphatic specific ablation of the VEGFR2 
gene leads to impaired lymphangiogenesis in mouse embryos and adult mice 
(Dellinger, Meadows et al. 2013). VEGFR2 becomes upregulated in angiogenic 
conditions and is a critical component of tumor vascularization (Claesson-Welsh and 
Welsh 2013). 
 
4.1.6 VEGFR3  
 Fms-like tyrosine kinase 4 (FLT4) was cloned from the human HEL 
erythroleukemia cell cDNA library (Pajusola, Aprelikova et al. 1992). VEGFR3 is a 
195 kDA transmembrane tyrosine kinase whose fifth Ig-like domain is proteolyticaly 
cleaved, and the subunits are linked together by a disulphide bond (-S-S-) (Pajusola, 
Aprelikova et al. 1994, Lee, Gray et al. 1996). VEGFR3 has two ligands, VEGFC and 
VEGFD. It was reported that stimulation with VEGFC or VEGF is able to induce the 
formation of VEGFR2/VEGFR3 heterodimers in vitro that display an altered 
phosphorylation-site pattern compared to VEGFR3 homodimers (Dixelius, Makinen 
et al. 2003, Nilsson, Bahram et al. 2010). VEGFR3 phosphorylation by c-Src can be 
triggered by adhesion to the ECM through integrin β1, in a ligand-independent way 
(Wang, Zhang et al. 2001, Galvagni, Pennacchini et al. 2010). 
VEGFR3 exists in two spliced variants (Pajusola, Aprelikova et al. 1993), as 
well as in a truncated, soluble form in the mouse cornea, that has been suggested to 
play a critical role in the lack of corneal lymphatic vessels (Singh, Tiem et al. 2013). 
 During embryogenesis VEGFR3 is expressed in BECs starting at E8.5 and is 
required for the remodeling and maturation of the developing vascular plexus; as a 
result embryos deficient for VEGFR3 die at E9.5 (Dumont, Jussila et al. 1998). 
Surprisingly, embryos deleted for both VEGFR3 ligands (VEGFC and VEGFD) do 
now show any blood vascular defects, but rather phenocopy the VEGFC deleted 
embryos (Haiko, Makinen et al. 2008). This suggests either that another ligand for 
VEGFR3 exists, or that the receptor functions in a ligand-independent manner 
during an early developmental stage. As development proceeds, VEGFR3 
expression becomes gradually downregulated in BECs and at around E14.5-15.5 
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becoms restricted to LECs (Kaipainen, Korhonen et al. 1995). Inhibition of VEGFR3 
signaling during late embryonic development or during the first two postnatal 
weeks in mice results in reversible lymphatic vessel regression, however the 
lymphatic vasculature of adult mice does not rely on ligand-dependent activation of 
VEGFR3 (Makinen, Jussila et al. 2001, Karpanen, Wirzenius et al. 2006). In the 
zebrafish, VEGFR3 drives sprouting angiogenesis in the developing intersegmental 
arteries (Covassin, Villefranc et al. 2006). 
In the adult, VEGFR3 is expressed in LECs and transduces proliferation, 
migration, and survival signals (Makinen, Veikkola et al. 2001). Furthermore 
VEGFR3 is expressed in high endothelial venules (HEVs) and fenestrated capillaries 
of several organs including the bone marrow, spleen, liver, kidney glomerulus and 
endocrine glands (thyroid, parathyroid, adrenals and adenohypophysis) 
(Lymboussaki, Partanen et al. 1998, Partanen, Arola et al. 2000). VEGFR3 expression 
becomes upregulated in angiogenic endothelia, for example in the tumor and wound 
vasculature, or following VEGF stimulation (Valtola, Salven et al. 1999, Paavonen, 
Puolakkainen et al. 2000, Partanen, Arola et al. 2000, Witmer, van Blijswijk et al. 2001, 
Laakkonen, Waltari et al. 2007). VEGFR3 expression in blood endothelia has been 
implicated in the maintenance of blood vessel integrity during angiogenesis (Kubo, 
Fujiwara et al. 2000) by modulating sensitivity to VEGFR2 (Matsumura, Hirashima 
et al. 2003). Other sites of VEGFR3 expression are neurons and astrocytes in the 
mouse and rat (Le Bras, Barallobre et al. 2006, Hou, Shin et al. 2011), as well as 
mouse neural stem cells, where it promotes neurogenesis after VEGFC stimulation 
(Calvo, Fontaine et al. 2011). VEGFR3 is expressed in motoneurons in zebrafish 
(Kwon, Fukuhara et al. 2013), where it transmits trophic/guidance signals and may 
participate in the pathophysiology of central/peripheral nervous system 
(CNS/PNS) diseases. VEGFR3 is expressed in dendritic cells during corneal 
inflammation (Hamrah, Chen et al. 2003), in conjunctival monocytes/macrophages 
(Hamrah, Chen et al. 2004) and in recruited monocytes/macrophages in tumors 
(Skobe, Hamberg et al. 2001b) and in wounds (Saaristo, Tammela et al. 2006). Finally 
VEGFR3 can be found in megakaryocytic progenitor cells, where it may regulate 
megakaryopoiesis (Thiele, Krishnan et al. 2012) and in the corneal epithelium, 
contributing to corneal avascularity (Cursiefen, Chen et al. 2006). Given the 
importance of VEGFR3 signaling in lymphangiogenesis, VEGFR3 is critically 
involved in tumor-associated lymphangiogenesis and lymphatic metastasis (He, 
Rajantie et al. 2005, Lin, Lalani et al. 2005, Roberts, Kloos et al. 2006), representing an 
attractive target for anti-lymphangiogenic therapies in cancer.   
 
4.2 Notch  
 Notch signaling is an evolutionarily conserved pathway that plays a central 
role in cell fate specification and differentiation, and has pleiotropic effects during 
embryonic development and adult life (Artavanis-Tsakonas, Matsuno et al. 1995). 
The Notch gene was originally identified and characterized in Drosophila 
melanogaster (Mohr 1919, Wharton, Johansen et al. 1985). In mammals the Notch 
signaling pathway consists of four Notch receptors (Notch1-4) and five ligands 
(Jagged1-2 and Delta-like [DLL] 1-3). In the blood vascular system ECs express 
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Notch 1 and 4, Jagged1-2, DLL1 and DLL4, while SMCs express Notch1 and 3 and 
Jagged1 (Kume 2009). 
Notch ligands and receptors are large single-pass transmembrane proteins 
containing epidermal-growth-factor (EGF) repeats in their extracellular domains. 
Notch ligands contain an N-terminal DSL domain that is required for interactions 
with their receptors, while the intracellular domain of Notch receptors consists of a 
RAM domain, six ankyrin (Ank) repeats and a C-terminal PEST domain, as well as 
nuclear localization signals. Notch signaling requires contacts between neighboring 
cells and upon ligand binding the Notch receptor is proteolyticaly cleaved twice, 
first just outside of the plasma membrane by the ADAM17 metalloprotease (also 
known as TNFα-converting enzyme, TACE) and then in the cytoplasmic side by a γ-
secretase complex, releasing the Notch intracellular domain (NICD). The NICD then 
translocates to the nucleus and forms a trimeric complex with the DNA-binding 
protein CSL (also known as recombination signal sequence-binding protein J, RBP-J), 
and the coactivator MAM. In the absence of NICD, CSL functions as a transcriptional 
repressor but interaction with NICD turns CSL to an activator by corepressor 
displacement and recruitment of coactivators, resulting in derepression of 
transcription of several Notch target genes, including the basic helix-loop-helix 
(bHLH) transcriptional factors hairy/enhancer of split (HES, HEY) (Borggrefe and 
Oswald 2009) (Figure 3). Apart from the aforementioned “canonical” Notch 
pathway, a “non-canonical” Notch pathway also exists, which is CSL independent 
and involves negative regulation of Wnt/β-catenin signaling by Notch (Le Gall, De 
Mattei et al. 2008, Andersen, Uosaki et al. 2012). 
 
 
Figure 3. The Notch signaling pathway. 
Both Notch ligands and receptors are 
transmembrane proteins expressed in 
adjacent cells. Upon receptor/ligand 
interaction, the ADAM 
metalloproteinase TACE cleaves the 
extracellular portion of the Notch 
protein. The extracellular domain 
together with the ligand are then 
endocytosed by the signal-sending cell. 
A γ-secretase cleaves the remaining part 
of the Notch protein in the signal-
receiving cell and releases the Notch 
intracellular domain, which activates the 
transcription factor CSL, resulting in the 
transcription of Notch target genes such 
as HEY, HES and NRARP. CoR: co-
repressors, HDAc: Histone deacetylase, 
MAML: Mastermind-like, HAc: Histone 
acetyltransferase, NECD: Notch 
extracellular domain, NICD: Notch 
intracellular domain. Modified from 
(Phng and Gerhardt 2009). 
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Notch signaling is indispensable for the proper development of the 
vasculature (Hofmann and Iruela-Arispe 2007). Notch1 mutants die at E9.5 due to 
cardiovascular and other defects (Swiatek, Lindsell et al. 1994, Conlon, Reaume et al. 
1995, Krebs, Xue et al. 2000, Limbourg, Takeshita et al. 2005) and Notch3 null mice 
show arterial differentiation defects (Domenga, Fardoux et al. 2004). While Notch4-
/- mice are phenotypically normal, compound loss of Notch1 and Notch4 results in 
a more severe vascular phenotype than Notch1 homozygous LOF, indicating 
overlapping functions of the two receptors during vascular development (Krebs, 
Shutter et al. 2004). On the other hand, loss of Notch ligands Jagged1 and DLL1 
results in embryonic death between E10.5-E12, due to vascular defects and 
hemorrhage (Hrabe de Angelis, McIntyre et al. 1997, Xue, Gao et al. 1999). DLL4 
haploinsufficient mice fail to remodel their primitive vascular plexus and form 
arteries, and die at E9.5. DLL4 haploinsufficiency is strain dependent and highlights 
the dosage-sensitive importance in Notch signaling (Duarte, Hirashima et al. 2004, 
Gale, Dominguez et al. 2004). 
 
4.2.1 Notch signaling in arterial-venous specification 
 Arteries and veins have different gene expression profiles, with arterial ECs 
expressing Notch1, NP1 and EphrinB2, and venous ECs expressing EphB4 and NP2 
(Wang, Chen et al. 1998, Herzog, Kalcheim et al. 2001). Arterial and venous identities 
are established early in development, before the initiation of hemodynamic flow, 
indicating the existence of a genetic program, which defines EC identity (le Noble, 
Fleury et al. 2005). Notch signaling plays a critical role in arterial specification, by 
repressing venous fate. Mutations in Notch pathway components result in 
loss/missexpression of artery/vein specific markers, defective artery formation and 
arteriovenous shunts (Roca and Adams 2007). In mice, the nuclear receptor COUP-
TFII suppresses Notch signaling and promotes venous differentiation (You, Lin et al. 
2005), while DLL4 heterozygosity results in lack of arterial marker expression and 
artery malformation (Gale, Dominguez et al. 2004, Krebs, Shutter et al. 2004). In 
zebrafish, Sonic Hedgehog induces VEGF expression, which in turn upregulates 
Notch in the aorta and controls arterial differentiation (Lawson, Scheer et al. 2001, 
Lawson, Vogel et al. 2002). Furthermore, the FOXC transcription factors FOXC1 and 
FOXC2 have been shown to act upstream of Notch in the regulation of arterial 
specification, and to activate directly the DLL4 and HEY2 promoters (Seo, Fujita et al. 
2006, Hayashi and Kume 2008). Finally Notch signaling is required for proper 
formation and patterning of postnatal mouse arteries, as well as blood vessel 
maturation, especially with respect to veins and perivenous capillaries (Ehling, 
Adams et al. 2013). 
 
4.2.2 Notch signaling in tip-stalk cell specification 
 Notch is a major determinant of cell fate and of the establishment of tip/stalk 
cell identity during sprouting angiogenesis. In the mouse retina the VEGF gradient 
produced by astrocytes provides a scaffold for tip cells to extend their filopodia 
towards higher VEGF concentrations. Although all ECs are exposed to the VEGF 
gradient, tip cells form only at intervals in the vascular front, based on DLL4/Notch 
activity. VEGF and hypoxia upregulate DLL4 expression in some ECs, which 
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preferentially acquire the tip cell position. Tip cells activate Notch signaling in their 
neighboring cells that adopt the stalk cell fate. Subsequently, Notch activation 
suppresses DLL4 expression (Gerhardt, Golding et al. 2003, Patel, Li et al. 2005, 
Noguera-Troise, Daly et al. 2006, Ridgway, Zhang et al. 2006, Williams, Li et al. 2006, 
Lobov, Renard et al. 2007, Suchting, Freitas et al. 2007, Roukens, Alloul-Ramdhani et 
al. 2010). Hence, tip cells express high levels of DLL4 while stalk cells express Notch 
target genes, like HEY1, HEY2, HES and NRARP (Claxton and Fruttiger 2004, 
Hellstrom, Phng et al. 2007, Hofmann and Iruela-Arispe 2007). This feedback loop, 
called lateral inhibition, allows the DLL4 expressing cell to further increase ligand 
production, intensifying initial small differences in ligand expression and resulting 
in a “salt and pepper” distribution of cells with diverse identities (Lewis 1998, 
Suchting, Freitas et al. 2007, Jakobsson, Bentley et al. 2009). The acquisition of the tip 
cell phenotype relies on randomly determined differences in VEGFR2 expression 
and other tip/stalk cell-specific genes, or small differences in the local VEGF 
microenvironment. As a result ECs expressing higher levels of VEGFR2 and DLL4 
(or lower levels of VEGFR1, Notch1, NRARP and Jagged1) have an advantage in 
maintaining the tip cell position (Blanco and Gerhardt 2013). Yet tip and stalk cells 
continuously and dynamically swap their positions, indicating a constant “battle for 
the lead” that depends on relative VEGFR2 levels and DLL4 expression (Bentley, 
Gerhardt et al. 2008, Bentley, Mariggi et al. 2009, Jakobsson, Franco et al. 2010). 
Another player in tip cell selection is Jagged1. Jagged1 is a weak Notch agonist that 
localizes mainly to stalk cells. It promotes tip cell formation by antagonizing the 
ability of DLL4 to activate Notch. It has been suggested that glycosylation of Notch 
by the glycosyltransferase Fringe enhances or reduces the response of Notch 
stimulation by DLL4 or Jagged1 binding respectively (Benedito, Roca et al. 2009). 
NRARP is also expressed in stalk cells where it limits Notch activity at vessel 
branching points in order to promote EC proliferation and stability (Phng, Potente et 
al. 2009). Notch has been shown to specify stalk cell identity by cooperating with the 
bone morphogenetic protein (BMP) signaling (Larrivee, Prahst et al. 2012, Moya, 
Umans et al. 2012). 
Given the significance of Notch signaling in restricting tip cell behavior, loss 
of Notch signaling by pharmacological or genetic means leads to increased filopodia 
formation, sprouting and branching, while Notch activation has the opposite effects 
(Hellstrom, Phng et al. 2007, Lobov, Renard et al. 2007, Suchting, Freitas et al. 2007). 
VEGFR2 upregulation and VEGFR1 downregulation following Notch LOF could 
partially explain the observed hypervascular phenotypes. 
 
4.2.3 Notch and VEGFR signaling 
 Both VEGFR and Notch signaling pathways are major regulators of 
angiogenesis and they interact in multiple ways (Benedito and Hellstrom 2013). 
VEGF acts upstream of Notch by inducing the expression of DLL4 in the ECs. 
Blocking VEGF decreases DLL4 expression, and Notch activation reduces VEGFR2 
levels in vitro, in the mouse retina and in tumors (Liu, Shirakawa et al. 2003, Patel, Li 
et al. 2005, Noguera-Troise, Daly et al. 2006, Ridgway, Zhang et al. 2006, Lobov, 
Renard et al. 2007, Shawber, Funahashi et al. 2007, Suchting, Freitas et al. 2007, 
Harrington, Sainson et al. 2008, Jakobsson, Franco et al. 2010). Yet, despite the 
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multiple lines of evidence that VEGF/VEGFR2 signaling is required upstream of 
DLL4 upregulation and Notch activation, a recent study that utilized conditional 
endothelial specific deletion of VEGFR2 in neonatal mice suggested that DLL4 is still 
expressed in ECs lacking VEGFR2 signaling, and that VEGFR2 levels are not altered 
upon Notch inhibition. In this study, ECs without VEGFR2 could still hypersprout 
under low Notch signaling conditions, and inhibition of VEGFR3 tyrosine kinase 
was able to restrict excessive sprouting associated with Notch LOF (Benedito, Rocha 
et al. 2012).  
Notch regulates also the expression of other VEGFRs. VEGFR1 and sVEGFR1 
are induced by Notch activation (Suchting, Freitas et al. 2007, Harrington, Sainson et 
al. 2008, Funahashi, Shawber et al. 2010, Benedito, Rocha et al. 2012). VEGFR3 is 
downregulated by Notch in vivo in zebrafish, and Notch LOF upregulates VEGFR3 
expression (Siekmann and Lawson 2007). However some in vitro studies show that 
VEGFR3 is upregulated by Notch (Shawber, Funahashi et al. 2007). Discrepancies 
between in vivo and in vitro results highlight the importance of the cellular context in 
which Notch signaling is studied. 
   
4.3 Other VEGF receptors 
4.3.1 Neuropilins 
 Neuropilins are single transmembrane proteins with a small cytoplasmic 
domain and no catalytic function (Fujisawa, Kitsukawa et al. 1997). Originally 
identified as receptors for class III semaphorins mediating repulsive signals during 
axonal growth (Raper 2000), neuropilins were later found to form complexes with 
VEGFRs. NP1 is a co-receptor for VEGFR2, enhancing its activity in the presence of 
VEGF165 (Whitaker, Limberg et al. 2001, Soker, Miao et al. 2002). Interestingly in trans 
VEGFR2/NP1 complex formation has been shown to inhibit angiogenesis and to 
promote endothelial quiescence (Koch, van Meeteren et al. 2014). NP1 can act also as 
a co-receptor for VEGFR1 (Soker, Miao et al. 2002) and VEGFR3 (Karpanen, 
Heckman et al. 2006). PLGF, VEGFB, VEGFC and VEGFD are also able to bind NP1 
(Migdal, Huppertz et al. 1998, Makinen, Olofsson et al. 1999, Gluzman-Poltorak, 
Cohen et al. 2000, Karpanen, Heckman et al. 2006). NP1 is mainly expressed in 
arterial endothelium (Herzog, Kalcheim et al. 2001, Moyon, Pardanaud et al. 2001) 
and NP1 deleted mice, as well as endothelial-specific NP1 mutants, die at 
midgestation due to defects in vessel formation (Kawasaki, Kitsukawa et al. 1999, Gu, 
Rodriguez et al. 2003). Although mice lacking the cytoplasmic domain of NP1 are 
viable, displaying only minor arteriovenous patterning defects, NP1 has been shown 
to act in an cell-autonomous way to support tip cell function in ECs (Fantin, Schwarz 
et al. 2011, Fantin, Vieira et al. 2013). Mice carrying a mutation of tyrosine 297 in NP1 
show reduced affinity to VEGF binding, impaired NP1/VEGFR2 complex formation 
and attenuated NP1 expression. Surprisingly these NP1 hypomorpic mutants 
display a milder phenotype than the NP1 knockout mice, suggesting that NP1 has 
also VEGF-independent roles during development (Fantin, Herzog et al. 2014). 
NP2 binds several VEGF family members, including VEGF and PLGF 
(Neufeld, Cohen et al. 2002), as well as VEGFC and VEGFD (Karpanen, Heckman et 
al. 2006). NP2 interacts with VEGFR3 (Karpanen, Heckman et al. 2006) and regulates 
lymphatic vessel sprouting (Xu, Yuan et al. 2010). NP2 is mainly expressed in veins 
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and lymphatic vessels, and homozygous NP2 mutants display reduced number and 
size of small lymphatic vessels (Yuan, Moyon et al. 2002). Remarkably, compound 
inactivation of both NP1 and NP2 results in embryonic death at E8.5 due to severe 
defects in vascular plexus formation (Takashima, Kitakaze et al. 2002), implying 
redundant NP signaling during early vascular development. 
 
4.4 Integrins and the ECM 
 Integrins are transmembrane heterodimers, composed of α and β subunits, 
that bind to matrix proteins, such as collagen, fibronectin, vitronectin and laminin 
(Silva, D'Amico et al. 2008). VEGFR2 forms complexes with αvβ3 integrin upon 
VEGF stimulation, and this is crucial for full VEGFR2 activity and angiogenesis. 
VEGFA induces phosphorylation of the β3 subunit, resulting in integrin activation, 
interaction with VEGFR2, amplification of VEGFR2 phosphorylation, and activation 
of Src (Pampori, Hato et al. 1999, Masson-Gadais, Houle et al. 2003, Mahabeleshwar, 
Feng et al. 2006, Mahabeleshwar and Byzova 2008, Mahabeleshwar, Chen et al. 2008). 
Potentiation of VEGFR3 signaling may happen via interaction of the receptor with 
integrin α5β1 after VEGFC stimulation (Zhang, Groopman et al. 2005). VEGF, 
VEGFC and VEGFD can bind directly to integrin α9β1, contributing to pathological 
angio- and lymphangiogenesis, and mice deficient for integrin α9β1 die after birth 
due to chylothorax (Vlahakis, Young et al. 2005). Finally, stimulation of integrin β1 
by collagen or fibronectin promotes VEGFR3 phosphorylation in a ligand-
independent manner, through Src (Wang, Zhang et al. 2001, Galvagni, Pennacchini 
et al. 2010). 
Fibronectin is an adhesion and migration ligand for the ECs. Mice deficient in 
astrocytic fibronectin production display reduced EC migration and abnormal 
filopodia projections in the retina, due to inhibition of VEGF binding to fibronectin 
(Wijelath, Rahman et al. 2006), and to the loss of filopodia interactions with the 
fibronectin network through integrin α5β1 (Stenzel, Franco et al. 2011). Moreover, 
fibronectin, as well as collagen type I, associate with the vascular-specific secreted 
factor epidermal growth factor-like domain 7 (EGFL7), which has been shown to 
interact with Notch receptors and antagonize DLL4/Jagged1/Notch interactions 
(Schmidt, Paes et al. 2007, Nichol, Shawber et al. 2010).  
Laminin 411 is mainly expressed at the vascular front, where it restricts tip 
cell formation via interactions with α-β1 integrin heterodimers. This results in the 
transcriptional activation of DLL4 and Notch (Stenzel, Franco et al. 2011). In vitro, 
laminin 111 has been found to interact with α-β1 integrins and to regulate DLL4 
expression in the ECs. Interestingly, integrin α2β1 stimulation by laminin triggers the 
expression of the transcription factor FOXC2 (Estrach, Cailleteau et al. 2011). On the 
other hand FOXC2 regulates the expression of integrin β3 (Hayashi, Sano et al. 2008). 
 Heparan sulfate proteoglycans in the ECM also have important roles in 
vascular patterning. Heparin binding domains on VEGF165 and VEGF189, encoded by 
exons 6 and 7, allow binding of VEGF to the ECM, and the establishment of 
concentration gradients in tissues that provide patterning cues for the developing 
vasculature (Park, Keller et al. 1993). PLGF and VEGFB167 also contain heparin-
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binding domains (Hauser and Weich 1993). Interestingly while tip cells require 
controlled VEGF distribution in order to orient their filopodia and guide the 
angiogenic sprout, stalk cells rely principally on local VEGF concentrations for 
proliferation (Ruhrberg, Gerhardt et al. 2002). Binding of VEGF to ECM modifies its 
downstream signaling properties, as well as its ability to interact with the β1 
integrins (Chen, Luque et al. 2010). Finally, MMPs have been implicated in the 
cleavage of VEGF and its release from the ECM (Lee, Jilani et al. 2005). 
 
4.5 Other regulators of vascular development 
 Several other factors are involved in the process of angiogenesis and 
lymphangiogenesis (Adams and Alitalo 2007, Coso, Bovay et al. 2014). These include 
the angiopoietin/TIE system that plays an essential role in vessel growth, 
maturation and stability (Eklund and Saharinen 2013), the fibroblast growth factors 
(FGFs) that signal through fibroblast growth factor receptors (FGFRs) to promote 
angiogenic activity (Presta, Dell'Era et al. 2005), transforming growth factor-β (TGF-
β) and bone morphogenetic protein (BMP) signaling (Cai, Pardali et al. 2012), and 
platelet-derived growth factor B (PDGF-B)/platelet-derived growth factor receptor-β  
(PDGFR-β) signaling that is crucial for the recruitment of pericytes (Armulik, 
Abramsson et al. 2005). In addition, many neural axon guidance molecules are 
indispensable for capillary growth and vascular patterning; these include the 
Robo/Slit, Netrin/UNC5B, Semaphorin/Plexin and Ephrins/Eph RTKs signaling 
pathways (Adams and Eichmann 2010). Apart from the aforementioned “classic” 
factors several “nonclassic” angiogenesis stimulators have been identified as well, 
such as erythropoietin (EPO), angiotensin II (ANGII), endothelins (ETs) and others 
(Ribatti, Conconi et al. 2007). Finally various miRNAs are expressed specifically in 
the ECs and play key roles in vessel development (Liu, Krueger et al. 2011, Dang, 
Lawson et al. 2013). 
 
 
5. THERAUPETIC VIEWPOINTS  
 
5.1 Anti- and pro-angiogenic therapies 
5.1.1 Tumor angiogenesis modulation 
 Antiangiogenic therapies are based on the concept of blocking tumor 
vascularization (Folkman 1971). Given the central role of VEGF signaling in tumor 
angiogenesis, it is not surprising that all currently FDA approved angiogenesis 
inhibitors target the VEGF pathway (http://www.fda.gov/). These inhibitors 
include the VEGF inhibiting antibody bevacizumab (Avastin), the VEGFR1/VEGFR2 
fusion protein aflibercept that acts as a soluble decoy receptor, and multi-target 
tyrosine kinase inhibitors (including sorafenib, sunitinib, pazopanib cabozantinib, 
regorafenib, vandetanib and axitinib) that target principally VEGFRs and PDGFRβ 
(Welti, Loges et al. 2013). Despite the largely successful preclinical testing, 
angiogenesis inhibitors have had only modest efficacy in the clinical setting, posing 
new questions and challenges to the research community. Anti-angiogenic therapies 
often result in a transient clinical improvement, which is followed by tumor relapse 
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and regrowth (Ebos and Kerbel 2011). Several mechanisms of resistance to anti-
angiogenesis treatments have been proposed. Tumors may utilize alternative pro-
angiogenic signaling pathways, such as FGF2 or PLGF (Batchelor, Sorensen et al. 
2007, Kopetz, Hoff et al. 2010), may recruit bone-marrow pro-angiogenic cells that 
express pro-angiogenic cytokines (such as TAMs, TIE2 expressing macrophages 
[TEMs], VEGFR1+ haematopoietic progenitors, and CD11b+Gr1+ myeloid cells) 
(Pollard 2004, De Palma, Venneri et al. 2005, Kaplan, Riba et al. 2005, Shojaei, Wu et 
al. 2007), may “normalize” the vasculature by increasing pericyte coverage (Bergers, 
Song et al. 2003), and promote local invasion in order to gain access to normal tissue 
vasculature (Ebos, Lee et al. 2009, Narayana, Kelly et al. 2009, Paez-Ribes, Allen et al. 
2009). These alternative ways to sustain tumor growth independently of VEGF 
signaling underlie “evasive resistance” (Bergers and Hanahan 2008). On the other 
hand not all tumors are sensitive to anti-angiogenic treatments, thus showing 
“intrinsic resistance” (Shojaei and Ferrara 2007, Olson and Joyce 2013). 
 The exact mode of function of antiangiogenic therapies remains unclear. 
Apart from inhibiting angiogenesis, pruning of the tumor vasculature and depriving 
the cancer cells from oxygen and nutrients, they may block recruitment of bone 
marrow derived cells into the tumor (Ellis and Hicklin 2008) and reduce the amount 
and self-renewal potential of cancer stem cells (Beck, Driessens et al. 2011). 
Importantly, angiogenesis inhibitors may decrease excessive intratumoral VEGF 
levels, leading to “normalization” of the vasculature. The concept of the vasculature 
normalization could explain why VEGF inhibitors improve survival in cancer 
patients only when used in combination with 
chemotherapy/radiotherapy/immunotherapy (Inai, Mancuso et al. 2004, Tong, 
Boucher et al. 2004, Dickson, Hamner et al. 2007, Goel, Duda et al. 2011). Based on 
the vascular normalization hypothesis, anti-VEGF treatment may improve tumor 
blood vessel morphology and functionality, resulting in reduced vessel permeability 
(Yuan, Chen et al. 1996), reduced hypoxia (Lee, Heijn et al. 2000), and improved 
blood flow within the tumor (Wildiers, Guetens et al. 2003); thus permitting delivery 
of other anticancer drugs and preventing cancer cell intravasation and 
hematogenous metastasis (Jain 2005). Yet angiogenesis inhibitors may also affect the 
normal vasculature, and they demonstrate a large spectrum of adverse effects that 
include hypertension (Sane, Anton et al. 2004), renal dysfunction that manifests itself 
usually as proteinuria (Hayman, Leung et al. 2012), arteriovenous thrombotic events 
(Nalluri, Chu et al. 2008), cardiomyopathy and congestive heart failure (Ky, 
Vejpongsa et al. 2013), hemorrhage, and impaired wound healing (Chen and Cleck 
2009). 
 Another way to counteract tumor vascularization involves inhibition of Notch 
signaling, which results in the formation of a hyperbranched, poorly perfused and 
non-functional vascular network, leading to tumor ischemia (Noguera-Troise, Daly 
et al. 2006, Ridgway, Zhang et al. 2006, Scehnet, Jiang et al. 2007, Thurston, Noguera-
Troise et al. 2007). However, long term blockade of DLL4 has been shown to cause 
liver hemangiomas in mice (Li, Jubb et al. 2010). On the other hand, a soluble 
extracellular domain of Notch1 (“Notch1 decoy”) has been shown to block VEGF-
induced angiogenesis, and to inhibit tumor angiogenesis and growth in mice 
(Funahashi, Hernandez et al. 2008), plus showing synergistic effects with VEGF 
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blockade in reducing tumor vascularization and viability (Hernandez, Banerjee et al. 
2013). Yet, deregulation of Notch signaling may contribute to carcinogenesis in 
multiple ways. Compounds inhibiting Notch signaling (including blocking 
antibodies and γ-secretase inhibitors) are currently in Phase I clinical trials (Espinoza 
and Miele 2013). 
 A plethora of novel antiangiogenesis inhibitors that target VEGF/VEGFR 
signaling and multiple other angiogenic pathways such as integrins, angiopoietins, 
TGFβ and fibroblast growth factor receptor (FGFR) (Clarke and Hurwitz 2013), are 
currently in various phases of clinical trials for the treatment of cancer 
(http://www.cancer.gov/clinicaltrials). Multitargeted and combination treatments 
could maximize the effectiveness of anti-cancer therapies and reduce the possibility 
of resistance development (Limaverde-Sousa, Sternberg et al. 2014). 
 
5.1.2 Ocular disease 
 Blocking VEGF has proved to be a successful approach for the treatment of 
neovascular eye diseases, including age-related macular degeneration (AMD), 
diabetic retinopathy (DR) and retinal vein occlusions (RVO) (Kim and D'Amore 
2012). Agents used or being currently in clinical trials include the VEGF neutralizing 
antibodies bevacizumab and ranibizumab, as well as the VEGF-trap aflibercept. 
These treatments have been a breakthrough in the field of intraocular vascular 
diseases due to their high efficacy and safety (Miller, Le Couter et al. 2013). 
 
5.1.3 Other angiogenesis-related diseases 
 Modulation of angiogenesis could be a valuable therapeutic approach for 
multiple conditions. Preclinical studies have shown that adenoviral delivery or 
intracerebroventricular infusion of VEGF could slow down the progression of 
amyotrophic lateral sclerosis (ALS), and a Phase I/II clinical trial utilizing VEGF as a 
treatment for ALS is currently ongoing (Keifer, O'Connor et al. 2014). Gene vector 
delivery of VEGFs has shown promising results in the ischemic myocardium and 
peripheral skeletal muscle of small and large animals, and several PhaseI/II clinical 
studies have been completed during the past years (Yla-Herttuala 2013). 
Proangiogenic gene transfer therapies have been successfully validated for use in 
revascularization of the CNS in mice (Gaal, Tammela et al. 2013). Finally, inhibition 
of angiogenesis associated with inflammation is widely investigated as a novel 
therapeutic approach to treat rheumatic diseases, atherosclerosis, inflammatory 
bowel disease and the metabolic syndrome (Costa, Incio et al. 2007). 
 
5.2 Anti- and pro-lymphangiogenic therapies  
5.2.1 Lymphatic metastasis 
 It has been estimated that 80% of solid tumor metastasis occurs via the 
lymphatic system (Warren, Ziyad et al. 2014). Since most cancer patients die due to 
metastatic disease (Coghlin and Murray 2010), the development of anti-
lymphangiogenic cancer therapies should be of importance. Tumors, perivascular 
cells and TAMs express lymphangiogenic factors such as VEGFC and VEGFD and 
induce lymphatic vessel sprouting, enlargement of peritumoral lymphatics and 
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lymph node lymphangiogenesis. Tumor associated lymphatics act as a conduit for 
tumor cells to disseminate and metastasize to sentinel lymph nodes and potentially 
to distant organs (Alitalo and Detmar 2012). Consequently, experimental 
overexpression or blocking of VEGFC or VEGFD signaling in animal models, 
promotes or suppresses respectively lymph node metastasis (Thiele and Sleeman 
2006). Elevated levels of VEGFC and VEGFD in human tumors correlate with high 
incidence of lymph node and distal metastasis, and poor patient prognosis (He, 
Karpanen et al. 2004, Hirakawa, Brown et al. 2007, Sleeman and Thiele 2009). On the 
other hand, while sentinel lymph node involvement has a high prognostic and 
staging value in some types of cancer, such as breast cancer and melanoma (Cousins, 
Thompson et al. 2014), it has been recently shown that systematic local nodal 
dissection does not have survival benefits in early breast cancer or in melanoma, 
respectively (Gershenwald and Ross 2011, Salhab, Patani et al. 2011, Meiers, Cil et al. 
2013, Rao, Euhus et al. 2013). Overall, it is still unclear how lymph nodes and the 
lymphatic route are involved in the formation of distal metastasis (Sleeman, 
Nazarenko et al. 2011) and further research is required to evaluate the potential of 
anti-lymphangiogenic therapies in cancer metastasis (Alitalo and Detmar 2012). 
Monoclonal antibodies targeting VEGFR3 and VEGFC are currently in Phase I 
clinical trials for anti-angiogenic tumor therapy (IMC-3C5, NCT01288989 and VGX-
100, NCT01514123 respectively). Finally, targeting tumor cell-aggregates within the 
tumor-draining lymphatic vessels using the cytotoxic compound verteporfin in 
combination with photodynamic therapy (that activates the dye) has been shown to 
prevent metastasis in preclinical models (Tammela, Saaristo et al. 2011). 
 
5.2.2 Lymphedema  
 Current treatments of secondary lymphedema include pressure garments, 
manual lymphatic drainage, intermittent pneumatic compression devices, low-level 
laser therapy, and exercise (Oremus, Dayes et al. 2012). Surgical procedures like 
liposuction, flap transfer, lymphatic bypass and lymph node transplantation are also 
utilized in the treatment of lymphedema (Mehrara, Zampell et al. 2011). Lymph 
node transfer in combination with growth factor therapy with VEGFC has increased 
the efficiency of incorporation of the lymph nodes into the lymphatic vasculature, 
providing a better preservation of the function of the transplanted lymph nodes in 
mice and pigs (Becker, Assouad et al. 2006, Tammela, Saaristo et al. 2007, 
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AIMS OF THE STUDY 
 
This study aims to elucidate the role of VEGFR3 in physiological and pathological 
angiogenesis, as well as the signaling interplay between VEGFR3, VEGFR2 and 
Notch during vessel formation. The specific aims of this thesis are: 
 
I  To study the function of VEGFR3 in embryonic, postnatal and pathological 
angiogenesis 
 
II To elucidate the molecular mechanisms underlying VEGFR3 signaling, in 
relation to Notch signaling 
 
III To clarify the relationship between VEGFR2, VEGFR3 and Notch signaling 
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MATERIALS AND METHODS 
 
A summary of the materials and methods used in these studies is given below. 
Detailed description is provided in the following text or in the original publications, 




Table I. Mouse lines  
Mouse line Description Reference/Source Used in 
Balb/c nu/nu, 
NMRI nu/nu 
Deletion of the Foxn1 gene, 
resulting in absence or thymus and 
immunodeficiency 
Taconic I 
Cdh5iCreERT2 Inducible Cre recombinase under 
the control of the Cdh5 gene 
promoter 
(Wang, Nakayama et al. 
2010) 
III 
Csf1op/op Mice currying the osteopetrosis 
spontaneous mutation (Csf1op)  
(Wiktor-Jedrzejczak, 
Ahmed et al. 1982) 
II 
Dll4+/LacZ The β-galactosidase (lacZ) gene has 
been inserted into the Dll4 locus, 
resulting in gene inactivation 
(Duarte, Hirashima et al. 
2004) 
I 
Foxc2+/− Deletion of the Foxc2 gene (Iida, Fujita et al. 1997) II 
K14-VEGF-E Overexpression of VEGF-E(NZ-7) 
under the control of the Keratin-14 
promoter. 
(Kiba, Sagara et al. 2003) I 
K14-VEGF165 Overexpression of human VEGF165 
under the control of the Keratin-14 
promoter 
(Zheng, Murakami et al. 
2006) 
I 
K14-VEGFR-3-Ig Overexpression of human VEGFR-
3-Ig fusion protein under the 
control of the Keratin-14 promoter 





Wild type outbred mice Taconic I, II 
PdgfbiCreERT2 Inducible Cre recombinase under 
the control of the Pdgfb gene 
promoter 
(Claxton, Kostourou et al. 
2008) 
II, III 
Prox1iCreERT2 Inducible Cre recombinase under 
the control of the Prox1 gene 
promoter 
(Bazigou, Lyons et al. 
2011) 
III 
Rip1Tag2 Expression of the oncogenic SV40 
Large T antigen transgene (TAg) in 
beta cells of the pancreatic islets, 
under the rat insulin promoter 
(Hanahan 1985) I 
ROSA26-R Expression of the β-galactosidase 
(lacZ) gene after Cre-recombination 
(Soriano 1999) II 
tdTomato Expression of the red fluorescent 
protein tdTomato, after Cre-
recombination  
(Madisen, Zwingman et 
al. 2010) 
III 
Vegfc+/LacZ The β-galactosidase (lacZ) gene has 
been inserted into the Vegfc locus, 
resulting in gene inactivation 
(Karkkainen, Haiko et al. 
2004) 
I, II 
Vegfd+/− Deletion of the Vegfd gene (Baldwin, Halford et al. 
2005) 
II 
Vegfr2+/LacZ The β-galactosidase (lacZ) gene has 
been inserted into the Vegfr2 locus, 
resulting in gene inactivation 
(Shalaby, Rossant et al. 
1995) 
III 
Vegfr2loxlox Vegfr2 conditional mouse (Haigh, Morelli et al. 
2003) 
III 
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Vegfr3+/KD Mice currying a heterozygous 
A3157T mutation in the tyrosine 
kinase domain of Vegfr3 
(Karkkainen, Saaristo et 
al. 2001) 
II 
Vegfr3+/LacZ The β-galactosidase (lacZ) gene has 
been inserted into the Vegfr3 locus, 
resulting in gene inactivation 
(Dumont, Jussila et al. 
1998) 
I 




Table II. Antibodies  




Alexa Fluor 594 
conjugated 
Invitrogen, B35132, clone 
MoBU-1 
I, II 
CD11b, mouse Rat monoclonal, Fitc 
conjugated 
BD Biosciences, 550282, 
clone M1/70 
I 
Collagen IV, mouse  Rabbit polyclonal Cosmo Bio (LB, 1403) II 
DLL4, mouse Goat polyclonal R&D Systems, AF1389 I, III 




F4/80, mouse Rat monoclonal Acris antibodies, BM4007, 
clone BM8 
I 
F4/80, mouse Rat monoclonal AbD Serotec, MCA497R II 
FITC Rabbit polyclonal Zymed/Invitrogen, 71-
1900 
I, II 
FOXC2, mouse Rat monoclonal (Furumoto, Miura et al. 
1999) 
II 
GFAP, cow Rabbit polyclonal Dako, Z0334 I 
GFP Rabbit polyclonal Torrey Pined Biolabs, 
TP401 
II, III 
hF4-3C5, human Mouse humanized 
monoclonal 
ImClone Systems, 
(Persaud, Tille et al. 2004) 
II 
LYVE1, mouse Rabbit polyclonal (Petrova, Karpanen et al. 
2004) 
I 
MECA-32, mouse Rat monoclonal BD Biosciences, 550563, 
clone MECA-32 
I 
NG2, mouse Rabbit polyclonal Chemicon/Millipore, 
AB5320 
I 
PECAM-1, mouse Hamster monoclonal Chemicon/Millipore, 
MAB1398Z, clone 2H8 
I 
PECAM-1, mouse Rat monoclonal BD Biosciences, 557355, 
clone MEC 13.3 
I, II, III 
PECAM-1, mouse Rat monoclonal, Fitc 
conjugated 
BD Biosciences, 553372, 
clone MEC 13.3 
I, II 
PDGFR-β, mouse Rat monoclonal eBioscience, 14-1402-82, 
clone APB5 
I 
Pimonidazole  Mouse monoclonal, Fitc 
conjugated 
Chemicon, HP2-1000 I 
Podoplanin, human Rabbit polyclonal (Kriehuber, Breiteneder-
Geleff et al. 2001) 
I 
PROX1, mouse Rabbit polyclonal (Karkkainen, Haiko et al. 
2004) 
III 
SMA, human Mouse monoclonal, Cy-3 
conjugated 
Sigma, C6189, clone 1A4 I 
TIE2, mouse Rat monoclonal eBioscience, CD202b, 
Clone: TEK4 
II 
VE-cadherin, mouse Rat monoclonal BD Biosciences, 550548, 
clone 11D4.1 
I 
VEGFC, human Rabbit polyclonal, #6 (Baluk, Tammela et al. 
2005) 
I, II 
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VEGFR1, mouse Rat monoclonal Imclone, clone 5B12 I 
VEGFR2, mouse Goat polyclonal R&D Systems, AF644 I 
VEGFR2, mouse Rat monoclonal BD Biosciences, 550549, 
clone AVAs-12α1 
I 




VEGFR3, mouse Goat polyclonal R&D Systems, AF743 I, II, III 
VEGFR3, mouse Rat monoclonal eBioscience, clone AFL4, 
16-5988 
I 
VEGFR3, mouse Rat monoclonal  (Pytowski, Goldman et al. 
2005), clone mF4-31C1 
I, II 
VEGFR3, human Mouse monoclonal (Jussila, Valtola et al. 
1998) 
I 
Von Willebrand factor, 
human 
Rabbit polyclonal Dako, A0082 I 
 
Table III. Recombinant adenoviruses 
Recombinant 
virus 
Description Reference/Source Used in 
AdLacZ Adenovirus that encodes β-
galactosidase 
(Laitinen, Zachary et al. 
1997) 
I 
AdVEGF165 Adenovirus that encodes human 
VEGF165  
(Enholm, Karpanen et al. 
2001) 
I, II 
AdVEGFB167 Adenovirus that encodes human 
VEGFB167 
(Lahteenvuo, Lahteenvuo 
et al. 2009) 
II 
AdVEGFC Adenovirus that encodes human 
VEGFC (full length) 
(Enholm, Karpanen et al. 
2001) 
I 
AdmVEGFD Adenovirus that encodes mouse 
VEGFD (full length) 
I I 
AdVEGFE Adenovirus that encodes VEGFE 
from the Orf(NZ7) virus 
(Wirzenius, Tammela et 
al. 2007) 
I 
AdVEGFR3-Ig Adenovirus that encodes human 
VEGFR3-Ig fusion protein 





pMX retrovirus that encodes 
mouse Dll4-ECTM- 
EGFP  








Holnthoner et al. 2009) 
II 
 
Table IV. Recombinant proteins 
Recombinant 
protein 
Description Reference/Source Used in 
Dll4-Fc Extracellular domain (ECD) of 
mDll4 fused to Fc domain of 
human IgG fusion protein 
(Zheng, Tammela et al. 
2011) 
II 
Jagged1 A Notch activating synthetic 
peptide, corresponding to the 
Δ/Serrate/LAG-2 domain of 
hJagged1 
(Weijzen, Velders et al. 
2002) 
I, II 
SC-Jagged1 A synthetic peptide with the 
scrambled sequence of the Jagged 
peptide  
(Weijzen, Velders et al. 
2002) 
I, II 
VEGF165 Recombinant human VEGF165 R&D Systems II 
VEGFCΔNΔC Recombinant VEGFC mimicking 
the human fully processed form of 
VEGFC 
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Table V. Cell lines 
Cell line Description Reference/Source Used in 
B16 C57BL/6 Mouse skin melanoma 
cells 
(Riley 1963) I 
B16-F10-Luc-
G5 








Primary mouse embryonic 
fibroblast 
(Holmborn, Ledin et al. 
2004) 
II 
G401  Human kidney cancer cells ATCC I 
HDBEC 
 
Human dermal blood endothelial 
cells 
PromoCell II 
HEK-293T  Human embryonic kidney cells, 
expressing the SV40-large T antigen 
ATCC I, II 
HeLa Human cervical cancer cells ATCC I 
LLC Mouse lewis lung carcinoma cells ATCC I, II 
mESC Mouse embryonic stem cells 
derived from the blastocyst stage of 
mouse embryos 
(Holmborn, Ledin et al. 
2004) 
II 





A highly lymphogenous metastatic 
subline of NCI-H460-N15, a human 
large-cell lung carcinoma, tagged 
with luciferase 
(Kozaki, Miyaishi et al. 
2000) 
(He, Rajantie et al. 2005) 
I 
 
2. METHODS  
 
Table VI. Methods summary 
Method Used in 
3D cultures of embryoid bodies II 
Adenoviral transduction of mice I, II 
Analysis of VEGFR3 phosphorylation following ECs adhesion to collagen I II 
Cell Culture I, II 
Cell transfections and transductions II 
ELISA I 
Generation and transduction of lentiviruses II 
Human samples I 
Immunofluorescence/Immunohistochemistry I, II, III 
Immunoprecipitation and immunoblotting II, III 
Metabolic labeling I 
Mice and treatments I, II, III 
Microscopy I, II, III 
Mouse embryos stimulation with growth factors I, II 
PI3K activity assay II 
Production and purification or Dll4-Fc II 
Statistical analysis I, II, III 
Superovulation I, II 
Real-time quantitative PCR I, II, III 
TEM I 
Tumor experiments I, II 
Vessel morphometry analysis I, II, III 
X-gal staining I, II 
 
3D cultures of embryoid bodies  
Embryonic stem cells were cultured on a layer of irradiated DR4 mouse embryonic 
fibroblasts in the presence of leukemia inhibitory factor (LIF). Cells were cultured for 
two passages without feeders, trypsinized, depleted of LIF, followed by mixing of 
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wild-type (DsRed) and Vegfr3+/LacZ cells in a 1:1 ratio and then left in suspension (day 
(D) 0). On D4, embryoid bodies were embedded in a polymerized collagen I gel with 
the addition of 30 ngml−1 mVEGF164 (Peprotech) with dimethylsulphoxide or DAPT 
(5 µM, Sigma-Aldrich). Medium was changed on D6 and every day thereafter. 
 
Adenoviral transduction of mice  
Adenoviruses encoding human VEGF165, VEGFB167 human full-length VEGFC, 
mouse VEGFD, the Orf(NZ7) virus-encoded VEGFE, or LacZ were injected 
intradermally into the ears of mice. A total of 2×108 plaque-forming units of each 
virus were injected in a volume of 50 µl. The mice were euthanized and perfusion-
fixed 5 (II) or 6 (I) days after injection, and the ears were collected and processed for 
whole-mount analysis or immersed in OCT medium (Tissue Tek). 
 
Analysis of VEGFR3 phosphorylation following ECs adhesion to collagen I  
HDBECs were transfected with pMX retrovirus encoding VEGFR3–StreptagII, 
detached using Accutase (PAA Laboratories) and plated on Collagen I or poly-L-
lysine (both 4µgcm−2). Cells were incubated for the indicated times with 1 µgml−1 
hF4-3C5, and 1 nM cediranib (Astra Zeneca) or 1 mM PP2 (Calbiochem). VEGFR3 
was precipitated from PLCLB lysates using Strep-Tactin beads (IBA). Proteins were 
analyzed by western blotting using antibodies to pTyr or VEGFR3. 
 
Cell culture 
NCI-H460-LNM35 cells (LNM35) (a gift from T. Takahashi), MKN45 cells (a gift 
from A. Ristimäki) were maintained in RPMI-1640 medium, whereas B16-F10, B16–
F10–Luc2–G5 cells, LLC cells and the G401 kidney cancer cells (CRL-1441) were 
grown in DMEM. Both media were supplemented with 2 mM l-glutamine, penicillin 
(100 Uml-1), streptomycin (100 µgml-1) and 10% fetal bovine serum (Autogen 
Bioclear). Zeocin was added as a selection marker to the cultures of B16–F10–Luc2–
G5 cells at the final concentration of 0.3 mgml−1. HDBECs (PromoCell) were 
maintained in endothelial cell growth medium (ECGM, PromoCell, C22120) with 
supplements provided by the manufacturer. 
 
Cell transfections  
For gene silencing experiments, HDBECs were transfected with human VEGFR3 or 
control siRNA (Thermo Scientific Dharmacon siGENOME ON-TARGETplus 




Patients diagnosed with disseminated colon adenocarcinoma underwent a standard 
chemotherapy treatment, followed by partial resection of the liver to eradicate 
metastases. Samples from the interface between normal and tumor tissue were 
immersed in 4% paraformaldehyde overnight at +4 °C, washed in PBS, incubated in 
25% sucrose overnight at +4 °C, embedded in optimal cutting temperature (OCT) 
medium and frozen. The study was approved by the Ethical Committee of the 
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Hospital District of Helsinki and Uusimaa according to the guidelines of the 
Helsinki declaration. Informed consent was provided by the patients. 
 
Generation and transduction of retroviruses 
An empty pMX vector or pMX vector encoding mDll4-ECTM-EGFP was transfected 
into 293-GPG (VSV-G) packaging cells using Fugene6 (Roche) according to the 
manufacturer’s instructions. Next day, the medium was changed and the viral 
supernatant was collected 4-7 days after the transfection. The supernatant was 
filtered with 0.45 µm filters (Millex) and stored at -70 °C. 150,000 HDBECs per well 
were plated on 6-well plates one day before transduction, exposed to 1 ml viral 
supernatant with 8 µg/mL Polybrene (Sigma) for 4 h, and incubated overnight with 
1.5 ml complete ECGM. The media was changed the following day and the cells 
were used the day thereafter. 
 
Immunofluorescence/Immunohistochemistry  
After euthanizing the mice, tissues were immersed in 4% paraformaldehyde, 
washed in phosphate buffered saline (PBS), and then processed for whole-mount 
staining (I, II, III) or immersed in OCT medium (Tissue Tek) (I, II). Whole mount 
retinas were stained with biotinylated Griffonia simplicifolia lectin (Vector 
Laboratories) in PB-Lec (10% MnCl2 1mM, 0.01% MgCl2 1M, 0.01% CaCl2 1M, in PBS 
with 0.1% Triton-X), followed by incubation with Alexa Fluor® streptavidin 
conjugates (Molecular Probes), to visualize the vasculature. For whole mount 
immunostaining of retinas, mesenteries, skins, tracheas, embryos and embryonic 
hindbrains were blocked in immunomix (5% non-immune donkey serum, 0.2% 
bovine serum albumin and 0.05% NaN3 in PBS with 0.3% Triton-X), incubated with 
primary antibodies, and washed with 0.3% PBS-Triton-X. 50 µm sections of tumors (I, 
II) or ovaries (I), 80 µm cross-sections of the duodenum (I), and 7-10 µm sections of 
skin (I, II) were fixed with cold acetone, washed with PBS and blocked with TNB 
(PerkinElmer). Following incubation with primary antibodies, the sections were 
washed with TNT buffer. The primary antibodies were detected with the 
appropriate Alexa 488, 594 or 647 secondary antibody conjugates (Molecular 
Probes/Invitrogen). All fluorescently labeled samples were mounted with 
Vectashield containing 4’,6-diamidino-2-phenylindole (DAPI, Vector Laboratories). 
Alternatively retinas, embryos or tumor sections were incubated in 5% hydrogen 
peroxide in methanol, followed by incubation with primary antibodies, biotinylated 
secondary antibodies (Vector Laboratories), and signal detection with the Avidin–
Biotin Complex kit (Vector Laboratories) or tyramide signal amplification (Perkin 
Elmer). Diaminobenzidine (Sigma or Chemicon) was used as the chromogen in both 
protocols (I). Stained mouse embryos were embedded in paraffin and sectioned in 
horizontal or sagittal orientation. Nuclear counterstaining was carried out with 
nuclear red (I). 
 
Immunoprecipitation and immunoblotting  
Equal amounts of cleared lysates from embryos, lungs or HDBECs were separated in 
7.5% or 10% Mini-PROTEAN TGX Precast gels (BIORAD). After blotting to 
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polyvinylidene fluoride membranes (Immobilon-P PVDF, Millipore), the proteins 
were detected using specific primary antibodies. The blots were probed using 
horseradish peroxidase-labeled secondary antibodies (Dako, Glostrup, Denmark) 
and the signal was visualized using the SuperSignal West Pico Chemiluminescent 
Substrate or the SuperSignal West Femto Maximum Sensitivity Substrate (Pierce, 
Rockford, IL, USA).!
 
Mice and treatments  
All studies were approved by the Committee for Animal Experiments of the District 
of Southern Finland. Transgenic mice were genotyped using suitable primers and 
standardized PCR protocols. Cre was induced by subcutaneous implantation of 
sustained release pellets (21 days) containing tamoxifen (25 mg, Innovative 
Research) (II), while newborn pups were injected intragastrically with 20 (II) or 50 µg 
(III) of 4-hydroxyamoxifen dissolved in 97% ethanol using a 10 µl Hamilton syringe. 
Pregnant females were given 2.5 mg of 4-OHT dissolved in 40% ethanol and 60% 
sunflower seed oil (Sigma), using a feeding needle at E10.5 or/and E11.5 (II). 
Successful deletion of the genes of interest was validated by immunohistochemistry, 
Western Blot and RT-qPCR. The mice received intraperitoneal injections of anti-
VEGFR3 and anti-VEGFR2 antibodies, or non-specific rat IgG (Dako) (30-40 mgkg-1 
in I for adults and 50 mgkg−1 in II for pups), and 60 mgkg-1 pimonidazole (I) or 0.2 
mg of BRDU (I, II). For the analysis of blood vessel density and blood vessel 
functionality mice were tail-vein-injected with 100 µl of 1 mgml-1 fluorescein-labeled 
Lycopersicon esculentum lectin (Vector Laboratories) under inhalation-anesthesia with 
isoflurane (Minrad Inc.) (I). Alternatively mice were intravenously administered 
with adenoviruses (1×109 p.f.u. per mouse) (I). DAPT (75-100 mgkg-1d-1) or control 
vehicle was dissolved in 10% ethanol and 90% sunflower oil and administered 
intraperitoneally to adult mice (I), and subcutaneously to pups (II, III). The small 
peptide mimetic of the Notch ligand Jagged1 (Jag1) or scrambled control peptide 
(SC-Jag1) was dissolved in 50% dimethylsulphoxide/50% sterile water, and 
administered subcutaneously at 10 mgkg−1 (I, II). The mice were anaesthetized with 
intraperitoneal injections of xylazine (10 mgkg−1) and ketamine (80 mgkg−1). 
 
Microscopy  
Fluorescently labeled samples were imaged using a confocal microscope (Zeiss LSM 
780, air objectives: x10 with numerical aperture [NA] 0.45, oil objectives: x40 with 
NA 1.3 and x63 with NA 1.4, or Zeiss LSM 5 Duo, air objectives x10 with NA 0.45, oil 
objectives x40 with NA 1.3 and x63 with NA 1.4, or Zeiss LSM 510 Meta, air 
objectives: x10 with NA 0.5, oil objectives x40 with NA 1.3 and x63 with NA 1.4), by 
using multichannel scanning in frame mode. Three-dimensional projections were 
constructed digitally from confocal z stacks. Signal co-localization was assessed from 
single confocal optical sections. Images of whole retinas, whole embryos and skin 
were acquired using tile scanning with a pinhole diameter >3.0 Airy units. X-gal and 
chromogen stainings were analyzed with a Leica DM LB transmitted light 
microscope (objectives ×10 with NA 0.25 and ×20 with NA 0.4). 10 µm thick sections 
of Rip1Tag2 tumors were analyzed with a Nikon Diaphot 300 immunofluorescence 
VEGFR3 and Notch signaling in angiogenesis     !
! 48!
microscope using Openlab 3.1.7. Software (Improvision) (I). Images were edited 
using PhotoShop software (CS4, CS5, Adobe). 
 
Mouse embryos stimulation with growth factors  
E10.5–E11.5 NMRI wild-type embryos were excised from amnionic sacs and placed 
in Dulbecco’s modified Eagle’s medium (DMEM) containing 0.2% bovine serum 
albumin (BSA) on ice. The embryos were injected through the cardiac outflow tract 
with 0.5 ml of DMEM containing 100 ngml−1 recombinant human VEGF165 (R&D 
Systems), 200 ngml−1 VEGFCΔNΔC, or 0.2% BSA. In each group, 10-15 embryos were 
used altogether. Embryos were placed in DMEM containing the same concentration 
of growth factors, incubated at 37 °C for 20 min and lysed in 1% Triton-X-100, 40 
mM Tris-HCl (pH 7.5), 150 mM NaCl, 2 mM Na3VO4, 100 µM 
phenylmethylsulphonyl fluoride, 50 mM NaF and 10 µgml−1 of both aprotinin and 
leupeptin. Insoluble materials were removed by centrifugation at 14,000 g for 15 min. 
 
PI3K activity assay  
PI(3)K activity was evaluated in HDBECs using FACE PI3-kinase p85 ELISA Kit 
(Active Motif) according to the manufacturer’s protocol. The signal was normalized 
to cell numbers by crystal violet staining. PI(3)K activity was measured with a 
microplate reader (Thermo Labsystems Multiscan Ascent). 
 
Production and purification of Dll4-Fc 
293T cells were transfected with Dll4-Fc or HSA (Fugene6 Transfection Reagent; 
Roche Diagnostics), and cultured in serum-free medium for 24 hours after 
transfection. After that, the supernatant was collected, concentrated 10 times with 
Centrifugal Filter Units (membrane size: 10 kDa; Millipore), aliquoted and frozen.  
 
Real-time quantitative PCR  
Total RNA was extracted and isolated from mouse lungs or retinas, and from 
HDBECs using RNeasy Mini Kit (Qiagen), or NucleoSpin RNA II Kit (Macherey-
Nagel). Samples were quality-controlled using a Nanodrop ND-1000 or BioSpec-
nano spectrophotometer. Reverse transcription into cDNA was performed using the 
DyNAmo™ cDNA Synthesis Kit (F-470L, Finnzymes), or iScript™ cDNA Synthesis 
Kit (Bio-Rad). Real-time quantitative PCR (RT-qPCR) was performed using TaqMan 
Gene Expression Assays (Applied Biosystems) and the DyNAmo™ Probe qPCR Kit 
(F-450S, Finnzymes), or iQ™ Supermix kit (Bio-Rad). RT-qPCR was carried out using 
a BIO-RAD C1000 Thermal cycler according to a standardized protocol. At least 
three independent experiments per condition were analyzed, and fold changes were 
calculated using the comparative CT method. 
 
Statistical analysis  
Statistical analysis was performed using IBM SPSS Statistics 18.0 or 20. A two-tailed 
Student's t-test, paired Student's t-test, One-Way ANOVA (Post-Hoc Test: Tukey 
HSD), Two-Way ANOVA (Post-Hoc Test: Tukey HSD), or a Holm-Sidak test were 
used for statistical analysis, and a P value of less than 0.05 was considered to be 





24 day-old female mice received one intraperitoneal injection of 5 international units 
(IU) pregnant mare serum gonadotropin (National Hormone and Peptide Program, 
Harbor-UCLA Medical Centre), followed by an injection of 5 IU human chorionic 
gonadotropin (Pregnyl) 47 h later. 72 or 84 h after stimulation of superovulation the 
mice were killed and their ovaries were collected for analysis. 
 
TEM  
The mice were perfusion-fixed with 4% formaldehyde in 100 mM phosphate buffer, 
pH 7.4, and slices of the kidneys were incubated in the same fixative overnight (16 h) 
at +10 °C. The samples were fixed with 2% glutaraldehyde in the same buffer for 1 h, 
and post-fixed with 1% buffered osmium tetroxide for 1 h, dehydrated and 
embedded in epon at room temperature (+22 °C). Sections were post-stained with 
uranyl acetate and lead and examined with a Jeol EX1200 II TEM operating at 60 kV. 
Images were acquired with an ES500W CCD camera (Gatan Corp.). 
 
Tumor experiments  
Tumor xenografts or syngeneic grafts were made by injecting 0.5–5×106 cells into the 
subcutaneous space in the abdominal flank of immunodeficient or transgenic mice 
respectively. Tumors were allowed to reach a volume of approximately 50 mm3, 
after which the mice were randomized into treatment groups. Tumors were 
measured in x, y and z dimensions using a digital caliper, and volumes were 
calculated using the ellipse formula (V = xyz/2). The experiments were terminated 
when the tumors reached a maximal size of 20 mm in diameter. 
 
Vessel morphometric analysis  
The vascular surface area in retinas was quantified as the isolectin B4-positive area 
from 10x (I, II) or 0.7x (III) confocal micrographs acquired of all intact quarters of the 
retina and at a similar distance from the optic nerve using Image J software (NIH, 
USA). Vessel branching points, sprouts and filopodia were counted manually from 
fluorescent micrographs of retinas using Image J (I, II, III). BrdU-positive endothelial 
cells were counted manually from 10x confocal z-stacks of BrdU and isolectin B4 
double-stained retinas (I, II). Mouse embryos were staged at E8.5–E9.5 according to 
the Edinburgh Mouse Atlas criteria, and the number of vessel branching points was 
manually counted from 10x confocal stacks in the head vasculature. The length and 
area of intersomitic vessels from between somites 12 and 15 was quantified from 10x 
micrographs obtained with the pinhole open (I). For hindbrain analysis (II), the 
number of sprouting vessels on the pial side and the number of branching points on 
the subventricular zone were determined in 3-6 randomly chosen 0.85 mm2 fields. 
Tumor vasculature surface area was analyzed from at least three 0.81 mm2 (I) or 1.69 
mm2 (I, II) micrographs from regions of uniform staining intensity, and quantified 
using Image J, while sprouts were counted manually. Lectin-stained vessels were 
counted from Rip1Tag2 tumor sections. PECAM-1-positive vessels in the ears or the 
LYVE1-positive vessel area in the intestines were quantified in a similar manner (I, 
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II). PROX1-positive lymphatic vessels from postnatal skins and tracheas (III) were 
quantified from 7.64 or 0.849 mm2 micrographs respectively, from regions of 
uniform staining intensity, and in a similar manner. DLL4 staining was manually 
quantified from 0.092 mm2 micrographs using Image J (III). All images used for 
quantification were three-dimensional projections of confocal z-stacks. The images 
used to quantify PROX1-positive lymphatic vessels in the skin were acquired using 
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RESULTS AND DISCUSSION 
 
1. VEGFR3 is a novel regulator of angiogenic sprouting (Study I) 
 
Although VEGFR3 is mainly expressed in the lymphatic endothelium in the 
adult (Alitalo, Tammela et al. 2005), Vegfr3 -/- mouse embryos die at E9.5 because of 
cardiovascular failure, before the formation of lymphatic vessels (Dumont, Jussila et 
al. 1998), and VEGFR3 is expressed in some fenestrated endothelia in the adult 
(Partanen, Arola et al. 2000). Furthermore VEGFR3 is upregulated in the tumor 
blood vasculature and in wounds (Valtola, Salven et al. 1999, Paavonen, 
Puolakkainen et al. 2000), and blocking VEGFR3 with monoclonal antibodies has 
been shown to suppress tumor angiogenesis (Laakkonen, Waltari et al. 2007). These 
data implied that VEGFR3 is involved in angiogenesis, urging us to investigate the 
VEGFR3-mediated angiogenic mechanisms. 
VEGFR3 expression was detected in several angiogenic vascular beds, for 
example in mouse and human tumors, in the developing embryonic vasculature, in 
the postnatal mouse retina, and in the ovarian follicles of superovulated female mice. 
VEGFR3 was mainly localized in endothelial tip cells, as has been previously shown 
for the developing segmental arteries in zebrafish (Siekmann and Lawson 2007). 
When VEGFR3 signaling was blocked using a blocking ligand-binding monoclonal 
antibody (31C1), angiogenic sprouting was inhibited in the retina and in tumor 
xenografts, and when this inhibitor was combined with an antibody blocking 
VEGFR2 signaling (DC101; representing the “golden standard” treatment in mouse 
tumor angiogenesis inhibition), this resulted in additive inhibition in tumor growth.  
To investigate the relationship between VEGFR2 and VEGFR3 signaling, 
angiogenesis was triggered in the mouse skin by overexpression of VEGFR2 specific 
ligands under the control of the keratin-14 promoter (K14-VEGF165 or K14-VEGFE). 
VEGFR3 was upregulated in the angiogenic blood vessels, suggesting that VEGFR2 
activation induced VEGFR3 expression (see also study III). Moreover, analysis of 
compound K14-VEGF165;K14-VEGFR3-Ig mice showed that simultaneous 
overexpression of VEGFR3-Ig, which binds to VEGFC and VEGFD and inhibits 
VEGFR3 activation, attenuated the angiogenic phenotype; although it did not have 
any profound effect on quiescent blood vessels in K14-VEGFR3-Ig mice. 
Interestingly, VEGFR3 stimulation by mouse VEGFD, a VEGFR3 specific ligand, 
which was delivered to the mouse ear skin by adenoviral gene transfer vector, did 
not promote sprouting angiogenesis unless combined with VEGFR2 stimulation. In 
the latter case the overexpression of ligands for both receptors resulted in a greater 
angiogenic effect than VEGFR2 stimulation alone. This suggests that VEGFR3 
dependent angiogenic signaling becomes significant in blood vessels only after 
VEGFR3 expression is primed by VEGFR2 activation (see also Study III). 
Inhibition of Notch signaling in the zebrafish embryo has been shown to 
upregulate flt4 expression in segmental arteries suggesting that Notch activation 
normally suppresses flt4 expression (Siekmann and Lawson 2007). In order to 
investigate the relationship between Notch and VEGFR3 signaling in mammals, we 
inhibited or activated Notch signaling in newborn mouse pups, using a γ-secretase 
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inhibitor (DAPT), or a small peptide that mimics the Notch ligand Jagged-1, 
respectively (Suchting, Freitas et al. 2007, Benedito, Roca et al. 2009). Loss of Notch 
signaling resulted in increased VEGFR3 mRNA and protein expression in the mouse 
retina, while Notch activation resulted in diminished expression of VEGFR3. 
Similarly, DLL4+/- retinas that have reduced Notch signaling, displayed increased 
levels of VEGFR3. Our results show that Notch activation downregulates VEGFR3 in 
endothelial tip cells, in a similar manner as reported previously for VEGFR2 (Lobov, 
Renard et al. 2007, Suchting, Freitas et al. 2007) (Figure 4). A similar loop has been 
described in zebrafish mutants lacking Notch ICD signaling (mind bomb mutants) or 
rbpsuh morphants (Lawson, Scheer et al. 2001, Siekmann and Lawson 2007), but not 
in dll4 morphants (Hogan, Herpers et al. 2009). These results highlight the significant 
differences that LOF of different components of the Notch pathway yield. Although 
Notch activity was already altered six hours after Notch inhibition, the expression of 
VEGFR3 was not changed before twelve hours, suggesting that intermediate 
effectors are required for Notch-mediated regulation of VEGFR3, or that Notch 
regulates VEGFR3 at the post-transcriptional level. This possibility is further 
supported by the notion that VEGFR3 protein levels are strongly upregulated in Rbpj 
knockout retinas, while VEGFR3 mRNA levels are only modestly increased 




Figure 4. Schematic illustration of the role of VEGFR3 in sprouting angiogenesis. VEGFR3 is highly 
expressed in endothelial tip cells, and becomes downregulated in stalk cells following Notch 
activation. However in conditions of low Notch signaling (for example in DLL4+/- mice or after 
treatment with γ-secretase inhibitors), the expression of VEGFR3 is upregulated in the whole 
vasculature. Adapted from study I. 
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In this study we used a variety of in vivo models to investigate the role of 
VEGFR3 in sprouting angiogenesis in mammals. We have shown that blocking 
VEGFR3 inhibits angiogenesis and displays additive properties with VEGFR2 
blockade, a finding that could be exploited in the context of multi-targeted cancer 
therapies. Later studies have confirmed the superiority of combined targeting of 
VEGFR2 and VEGFR3 in tumor angiogenesis inhibition (Matsumoto, Roufail et al. 
2013). Yet, one important aspect to consider is the possible side effects of VEGFR 
targeting. For example bevacizumab causes proteinuria and hypertension in humans 
(Hayman, Leung et al. 2012). Although VEGFR3 is mainly expressed in quiescent 
fenestrated endothelia in the adult, and thus represents potentially a safer anti-
angiogenic target, we performed an anatomical and functional screening of kidney 
function in K14-VEGFR3-Ig mice and in mice treated with VEGFR3 inhibitors. We 
did not observe any sign of kidney pathology at the ultrastructural level, neither 
pathological albuminuria or nephrosis. Although these preclinical data are very 
encouraging, mice and humans differ in multiple aspects with respect to their 
physiology; therefore clinical trials would be required to assess the safety of VEGFR3 
inhibitors. In early 2011, a humanized blocking antibody against VEGFR3 entered a 
Phase 1 clinical trial for patients with solid tumors by ImClone/EliLilly&Co 
(NCT01288989); this trial will address the safety of VEGFR3 inhibition in humans 
within the next years. Targeting VEGFR3 could be very useful clinically, as it could 
potentially block simultaneously tumor angiogenesis and lymph node metastasis, 
especially when used in combination with VEGFR2 inhibition (Matsumoto, Roufail 
et al. 2013). 
 
 
2. VEGFC/VEGFR3 signaling activates Notch signaling and facilitates the 
formation of stable vascular loops (Study II) 
 
VEGFR3 is expressed in mouse embryos already at E8.5 (Kukk, Lymboussaki 
et al. 1996) and VEGFR3 deficient embryos die at E9.5, due to defective vascular 
remodeling and maturation (Dumont, Jussila et al. 1998). Thus it has been impossible 
to study Vegfr3 deficient mice postnatally. So far LOF studies relied principally on 
systematic administration of blocking antibodies or inhibiting soluble receptors that 
can affect all cells expressing the receptor. In order to study the functions of VEGFR3 
exclusively in blood vessels, and to circumvent the embryonic lethality observed in 
Vegfr3-/- embryos, we employed conditional mutagenesis. We produced mice with 
conditional VEGFR3 alleles that express the Cre recombinase under the endothelial 
specific PDGFB promoter. Tamoxifen or 4-OH-tamoxifen administration was then 
used to activate Cre recombinase and to initiate recombination events in all vascular 
endothelia (Claxton, Kostourou et al. 2008, Haiko, Makinen et al. 2008).  
Surprisingly, endothelial specific deletion of VEGFR3 (Vegfr3iΔEC) resulted in 
a hypervascular phenotype with excessive filopodia formation in the postnatal 
mouse retina, the embryonic hindbrain, as well as in the tumor vasculature. 
Although our previous studies indicated that VEGFR3 is an angiogenesis activator, 
our subsequent results implied that it acts as an inhibitor. However the methods 
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used to disrupt VEGFR3 signaling in those studies have been qualitative different: in 
the first case we used monoclonal antibodies that inhibited ligand binding but left 
the intracellular domain of the receptor intact, while in the latter we removed the 
receptor completely from the BECs. Previous publications have shown that VEGFR3 
can be phosphorylated in vitro by collagen or fibronectin through their binding to β1 
integrin (Wang, Zhang et al. 2001). The phosphorylation of VEGFR3 by the ECM is 
ligand independent, since it occurs in the presence of a kinase inhibitor (MAZ51), or 
in a mutant, kinase dead receptor, and is mediated by Src. In this case Src produces a 
different phosphorylation pattern compared to the one induced by ligand activation 
of VEGFR3 (Galvagni, Pennacchini et al. 2010). In vivo deletion of both VEGFR3 
ligands (VEGFC and VEGFD) did not recapitulate the VEGFR3-/- phenotype, but 
instead these embryos mimicked the VEGFC null embryos and died due to 
lymphatic defects (Haiko, Makinen et al. 2008). This implies that in this 
developmental context the ligand-dependent functions of VEGFR3 are dispensable. 
We were able to confirm ligand-independent phosphorylation of the receptor in 
HDBECs that were stably transduced with the pMX–VEGFR3–StreptagII retrovirus. 
In vivo, the retinas of Vegfr3KD/lox mice, which exhibit VEGFR3 hypophosphorylation 
(Karkkainen, Saaristo et al. 2001), showed a similar hypervascular phenotype, 
suggesting that the observed phenotype does not result from perturbed ligand-
dependent VEGFR3 signaling, further indicating that the receptor exhibits two 
modes of action, which are  ligand-dependent or  ligand-independent. 
Since the phenotype resulting from endothelial specific VEGFR3 deletion 
resembled the Notch LOF phenotype, we explored possible perturbations of Notch 
signaling in our mutants. Indeed, several Notch target genes were downregulated in 
the Vegfr3iΔEC retinas, suggesting that Notch LOF underlies the phenotype. To 
confirm this, we performed a rescue experiment by administering a Notch agonist to 
Vegfr3iΔEC pups (Benedito, Roca et al. 2009). This was able to restore the retinal 
vasculature back to normal. We also tested the ability of VEGFR3 to activate Notch 
signaling in mosaic embryoid bodies and retinas consisting of VEGFR3+/LacZ and 
wild type endothelial cells (Jakobsson, Franco et al. 2010). The VEGFR3+/LacZ cells 
occupied preferentially the tip cell position in the developing sprouts, which is in 
agreement with reduced Notch signaling in these cells. Importantly, Notch signaling 
was unaltered in the retinas of pups treated with antibodies blocking VEGFR3, 
confirming that the ligand-dependent VEGFR3 signaling does not involve 
(canonical) Notch activation.  
To investigate whether VEGFR3 ligands are involved in VEGFR3 activation in 
angiogenic endothelium, we analyzed VEGFC and VEGFD heterozygous mice 
(Karkkainen, Haiko et al. 2004, Baldwin, Halford et al. 2005). VEGFD mutant retinas 
were indistinguishable from those of wild type littermates; however VEGFC 
heterozygotes displayed a hypovascular phenotype that was characterized by 
excessive vessel regression. Vessel regression is a normal process during maturation 
of vascular networks and results in the formation of empty “sleeves” of basement 
membrane that can be identified by collagen IV staining (Baluk, Morikawa et al. 
2003). Increased vessel regression, as seen in our VEGFC mutants, is likely a sign of 
vessel instability and inefficient fusion of tip cells to form vascular loops. Yet what 
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could be the source of VEGFC in the retina? In the developing mouse and zebrafish 
embryo the ECs have been shown to produce VEGFC (study I). Furthermore 
resident microglia has been implicated in vascular branching in the embryonic 
hindbrain and mouse retina, although these angiogenic effects are not mediated by 
VEGF expression by microglial cells (Fantin, Vieira et al. 2010, Rymo, Gerhardt et al. 
2011). We identified a subpopulation of TIE2 positive macrophages in P5 retinas that 
expressed VEGFC and were localized at sites of vascular remodeling behind the 
angiogenic front. TEMs have been shown to promote angiogenesis in tumors and 
remodeling tissues (De Palma, Venneri et al. 2005, Pucci, Venneri et al. 2009, Coffelt, 
Tal et al. 2010, Capobianco, Monno et al. 2011, Mazzieri, Pucci et al. 2011, Patel, 
Smith et al. 2013). Phenotypic analysis of op/op mice that lack macrophages 
revealed a similar phenotype as in the VEGFC heterozygotes, confirming the 
previously demonstrated role of these cells in branching anastomosis (Kubota, 
Takubo et al. 2009). Interestingly, both the VEGFC+/- and the op/op mice showed 
reduced levels of Notch activation, showing that ECs with low Notch signaling 
activity may be still unable to hypersprout in some conditions (see also III). 
To identify the molecular players downstream of VEGFR3 signaling, we 
stimulated HDBECs with VEGFC in the presence of a soluble Notch inhibitor (Dll4-
Fc), and found non-canonical induction of the Notch target genes HEY1, HEY2 and 
NRARP, indicating Notch activation. On the other hand, we did not detect Notch 
activation in the presence of a PI3K inhibitor. Silencing of VEGFR3 eliminated PI3K 
induction by VEGFC stimulation. This suggested that PI3K acts downstream of 
VEGFR3 to activate Notch in endothelial cells. PI3Ks are lipid kinases that are 
activated downstream of VEGFR2 and VEGFR3 in BECs and LECs, respectively 
(Graupera and Potente 2013), while PI3K activation by VEGFR3 has been previously 
shown in BECs only in the zebrafish (Herbert, Huisken et al. 2009). 
We subsequently identified the transcription factor FOXC2 as a further 
downstream component of the signaling pathway. FOXC2 was induced by VEGFC 
stimulation in HDBECs, and it was downregulated following VEGFR3 silencing. 
Vegfr3+/-;Foxc2+/- compound heterozygous mice recapitulated the phenotype of 
Vegfr3KD/lox mice, while single heterozygotes showed no defects, suggesting a possible 
genetic interaction of VEGFR3 and FOXC2 in developing blood vessels. FOXC2 is a 
member of the Forkhead transcription factor family that has been implicated in 
vascular development and disease (Kume 2008). FOXC2 has been shown to directly 
activate DLL4 and HEY2 (Hayashi and Kume 2008). This is in agreement with the 
hypothesis that VEGFR3 can activate Notch in a non-canonical way, via this 
transcription factor. 
In this study we used in vivo tools to describe a novel mode of action of 
VEGFR3. β1 integrin and ECM have been shown to trigger ligand-independent 
activation of VEGFR3 through Src kinase. Our results support a model were ligand 
binding activation of VEGFR3 generates pro-angiogenic signals, while ligand-
independent activation induces Notch signaling and restricts angiogenic sprouting. 
In addition, VEGFC/VEGFR3 signaling is able to activate Notch in a non-canonical 
manner at sites of vascular anastomosis and to mediate the phenotypic conversion of 
tip cells to stalk cells, and the formation of stable vascular loops (Figure 5). Our 
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studies identified the TIE2+ positive macrophages in the retina as the key cells 
producing VEGFC. Interestingly, VEGFC is produced by proangiogenic TIE2+ 
macrophages in corpus luteum during the early stages of pregnancy in mice (Care, 
Diener et al. 2013).  Yet the VEGFC+/- and op/op retinas did not display the typical 
Notch LOF phenotype, rather they were hypoplastic. This result is in agreement 
with VEGFR3-ligand-blocking studies, showing that the ligand-dependent arm of 
VEGFR3 promotes angiogenesis. In addition, macrophages produce a plethora of 
angiogenic factors, including VEGF (Xiong, Elson et al. 1998). Therefore loss of 
macrophages would disrupt VEGF/VEGFR2 signaling, which is a key pathway in 




Figure 5: Summary of the proposed function of VEGFC/VEGFR3 signaling in endothelial tip cells. 
(a) VEGFC expressing macrophages (purple) act as bridges between two tip cells, by activating Notch 
signaling and decreasing VEGF sensitivity. VEGFR3 is expressed in the tip cells, which upon VEGFR3 
LOF fail to sense VEGFC, activate Notch signaling and become stalk cells. This results in excessive 
amount of tip cells and a hypersprouting phenotype. Adapted from study II. (b) A schematic showing 




3. VEGFR3 cannot replace VEGFR2 in sprouting angiogenesis, while VEGFR2 is 
not essential for early postnatal lymphangiogenesis (Study III) 
 
VEGFR2 is a key element of Notch signaling, and has been shown to act 
upstream of DLL4 expression in endothelial tip cells. DLL4 subsequently activates 
Notch in adjacent stalk cells, which downregulate VEGFR2 expression in a negative 
feedback loop. In our previous studies (I and II), we demonstrated a similar mode of 
action of VEGFR3/Notch signaling in the mouse retina. On the other hand, the 
receptors form VEGFR2/VEGFR3 heterodimers in LECs and BECs, which appear to 
be important for angiogenic sprouting in mice and arteriogenesis in zebrafish 
(Dixelius, Makinen et al. 2003, Covassin, Villefranc et al. 2006, Nilsson, Bahram et al. 
2010). VEGFR2 activation induces VEGFR3 expression in mouse blood vessels 
(Study I), and genetic deletion of VEGFR3 prolongs VEGFR2 phosphorylation in 
BECs (Study II). To investigate the crosstalk of the receptors, and to circumvent the 
embryonic lethality of Vegfr2-/- and Vegfr3-/- mice, we deleted VEGFR2 and/or 
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VEGFR3 conditionally in newborn pups and analyzed postnatal angiogenesis and 
Notch signaling in the mouse retina. 
Endothelial specific deletion of VEGFR2 (Vegfr2iΔEC) in postnatal retina 
resulted in a hypoplastic vasculature, as previously published (Benedito, Rocha et al. 
2012). However, since the amounts of residual VEGFR2 protein expression in this 
model were not negligible (minimum 20% in lungs), we decided to increase the 
deletion efficiency by analyzing mice in which one VEGFR2 allele was constitutively 
inactivated and the other one was conditionally targeted (Vegfr2iΔEC/LacZ). 
Vegfr2+/LacZ retinas were indistinguishable from those in wild type littermates, but 
the Vegfr2iΔEC/LacZ retinas were severely hypovascularized, and showed areas of 
EC clustering. This 3-dimensional accumulation of ECs in the retina could be a sign 
of disrupted EC competition as has been previously reported in conditions of VEGF 
gradient loss (Jakobsson, Franco et al. 2010). It could be also a sign of the inability of 
the ECs to sense the VEGF gradient and migrate towards the retina periphery. The 
Vegfr2iΔEC/LacZ mice shower reduced Notch signaling, indicating that VEGFR2 is 
required for Notch activation.  
To investigate if VEGFR3 LOF supports ECs sprouting even in the absence of 
VEGFR2, we generated Vegfr2;Vegfr3iΔEC mice, and deleted both receptors in 
postnatal blood vessels. The compound deleted mice showed no difference in 
vascular density compared to Vegfr2iΔEC mice, suggesting that VEGFR2 signals 
upstream of VEGFR3 (see also study I) and that it is necessary to induce VEGFR3 
expression in angiogenic BECs. Interestingly, the Vegfr3iΔEC mice showed elevated 
levels of VEGFR2, indicating that VEGFR3 suppresses VEGFR2 (see also study II). 
Otherwise the Vegfr2;Vegfr3iΔEC retinas displayed abnormal ECs connections, as the 
VEGFC+/- retinas (study II). 
We next sought to determine the interplay between VEGFRs and Notch 
signaling. A recent study by Benedito et al. suggested that hypersprouting following 
Notch LOF is still possible via VEGFR3 signaling, even when VEGFR2 is missing 
(Benedito, Rocha et al. 2012). In their study VEGF2 LOF had no effect in Notch LOF 
mediated hypersprouting, while inhibition of VEGFR3 kinase activity by the kinase 
inhibitor MAZ51 was able to reduce excess filopodia and sprout formation upon 
DAPT treatment. Based on these results the authors suggested that VEGFR3 kinase 
activity, but not ligand binding-dependent signaling, is proangiogenic in ECs with 
low Notch signaling. A similar finding has been reported earlier in the zebrafish 
rbpsuh morphant, in which hypersprouting could be partially rescued by flt4 
morpholinos, and in the mutant expando, that carries a loss-of-function mutation in 
the kinase region of flt4, and rescues the dll4 LOF arterial hyperbranching 
phenotype (Hogan, Herpers et al. 2009). However, we were unable to detect any 
hyperspouting following Notch inhibition in our VEGFR2 mutants. Furthermore, 
genetic deletion of VEGFR3 did not restrict hyperspouting upon Notch LOF; on the 
contrary it exacerbated the phenotype. We could detect reduced numbers of tip cells 
in all conditions where VEGFR2 signaling was absent; there were fewer filopodia 
and less DLL4 staining, indicating that VEGFR2 is required by ECs to acquire the tip 
cell phenotype (Gerhardt, Golding et al. 2003, Patel, Li et al. 2005, Noguera-Troise, 
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Daly et al. 2006, Ridgway, Zhang et al. 2006, Williams, Li et al. 2006, Lobov, Renard 
et al. 2007, Suchting, Freitas et al. 2007, Jakobsson, Franco et al. 2010, Roukens, 
Alloul-Ramdhani et al. 2010). Importantly, although we have previously observed 
reduced DLL4 mRNA levels in retinas of Vegfr3iΔLEC pups (see study II), further 
analysis by immunohistochemistry showed that the DLL4 protein levels remain 
unaltered following VEGFR3 genetic deletion. This finding reinforces the idea that 
Notch activation by VEGFR3 occurs in a DLL4 independent manner. Another 
possibility is that DLL4 upregulation happens via VEGFR2-dependent post-
transcriptional regulation.  
Different perturbations in expression and activity of Notch ligands/receptors 
and VEGFRs could produce diverse, context-dependent EC responses and biological 
effects, depending on the particular ligands and receptors involved. Interestingly, 
other molecules such as laminins have been suggested to upregulate DLL4 
expression in BECs (Estrach, Cailleteau et al. 2011, Stenzel, Franco et al. 2011). Yet 
the specificity of the kinase inhibitor used by Benedito at al (MAZ51) has never been 
validated at the kinome level, and it has been shown to inhibit for example VEGFR2 
phosphorylation (Kirkin, Mazitschek et al. 2001). On the other hand the comparison 
of Vegfr2iΔEC and Vegfr2iΔEC/LacZ retinas implies that small amounts of VEGFR2 
are able to sustain angiogenesis to some extent, and could provide a gateway for 
hypersprouting upon DAPT treatment in the case of incomplete deletion.  
Although the ECs had low Notch levels, this did not result in the typical 
hypervacular phenotype accompanying Notch LOF, in the absence of the VEGFR2. 
This highlights the diverse fundamental functions of VEGFR2 signaling in ECs, 
including PLC-γ1 activation leading to EC proliferation via the MAP kinase pathway 
(Takahashi, Yamaguchi et al. 2001), PI3K activation leading to EC proliferation, 
differentiation and survival (Gerber, McMurtrey et al. 1998, Dayanir, Meyer et al. 
2001, Meyer, Latz et al. 2003), and phosphorylation of the adapter molecule Shb that 
drives EC migration (Holmqvist, Cross et al. 2004). Decreased EC numbers and 
reduced Notch activity have been also observed in the op/op mice, which lack 
macrophages that are a source of VEGF (Xiong, Elson et al. 1998), and in VEGFC+/- 
mice (see study II). In line with these observations, Vegfr2;Vegfr3iΔEC compound 
mice phenocopied the Vegfr2iΔEC mutants in terms of vascular density. Yet 
qualitative differences reminiscent of VEGFC+/- mice, like EC detachment from the 
vascular plexus, could be observed in the compound mutants, suggesting that some 
aspects of VEGFR3 angiogenic signaling are independent of VEGFR2. 
We also studied the functions of VEGFRs in postnatal lymphatic vessel 
growth and maturation. VEGFR3 is important for lymphatic vessel growth during 
the two first postnatal weeks in pups (Karpanen, Wirzenius et al. 2006), however the 
role of VEGFR2 in lymphatic vessels has remained unclear (Hong, Lange-
Asschenfeldt et al. 2004, Kajiya, Hirakawa et al. 2006, Wirzenius, Tammela et al. 
2007). We were able to confirm the importance of VEGFR3 by its genetic deletion 
exclusively in lymphatic vessels by using the lymphatic specific deletor 
Prox1iCreERT2 (Bazigou, Lyons et al. 2011) and by producing mice deleted of 
VEGFR3, VEGFR2, or both (Vegfr2iΔLEC, Vegfr3iΔLEC, and Vegfr2;Vegfr3iΔLEC 
respectively). The Vegfr3iΔLEC mice had fewer lymphatic vessels compared to their 
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wild type littermates, and were unable to sprout and mature normally. On the 
contrary the Vegfr2iΔLEC mice did not show any lymphatic vascular defects, 
suggesting that VEGFR2 signaling in LECs is not crucial at this developmental stage. 
Interestingly, a recent report by Dellinger et al. showed that conditional lymphatic 
deletion of VEGFR2 resulted in hypoplastic but functional lymphatic vessels in 
embryos and adult mice (Dellinger, Meadows et al. 2013). However, in this study 
constitutive VEGFR2 deletion was initiated already during embryonic development, 
resulting also in blood vessel defects, raising the possibility that the observed defects 
in adult mice originate from disruption of VEGFR2 signaling during lymphatic 
vessel development. In contrast, in our studies, lymphatics developed normally until 
birth. We performed a time-course analysis of VEGFR2 protein expression on 
postnatal lymphatic vessels, which showed that although the protein was 
completely absent at the time of analysis at P6, it is downregulated gradually with 
some minor expression still detected at P3. Taken together, these data raise the 
possibility that conditional mutants experienced VEGFR2 LOF for a period that was 
too short to produce a significant phenotype. Nevertheless, considering the dramatic 
changes following conditional VEGFR3 LOF in the same context, it is safe to 
conclude that VEGFR2 has a minor role –if any- in early postnatal lymphatic growth. 
Yet we cannot exclude the possibility that VEGFR2 deletion could have an effect on 
the lymphatic vessels at later timepoints or in adult mice. Further studies are 
required to investigate the role of VEGFR2 in late postnatal lymphatic growth, and 
lymphatic vessel maintenance in adults. 
In this study we used state of the art genetic tools to investigate the molecular 
interplay between VEGFRs and Notch in sprouting angiogenesis. Although 
conditional mouse models are characterized by a high degree of precision and 
reliability, our results highlight the importance of residual protein expression after 
Cre-recombinase induction that could obscure the interpretation of the results, 
especially in experiments that are performed during a short period, like in postnatal 
retina studies. A recent paper by D’Amico et al. reported a similar finding with 
conditional EC-specific deletion of TIE1; in this study 10% residual expression of 
TIE1 receptor rescued the hypovascular phenotypes observed in Tie1iΔEC/LacZ mice, 
which showed maximum deletion levels (D'Amico, Korhonen et al. 2014). On the 
other hand, we established a functional loop in which VEGFR2 activates VEGFR3 
expression in blood vessels, which subsequently suppresses VEGFR2 expression, 
producing a negative feedback loop. Finally, we showed for the first time that 
VEGFR2 expression on the lymphatic vasculature is dispensable during postnatal 
growth and remodeling of lymphatic vessels, and that it cannot replace VEGFR3 
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CONCLUSIONS AND FUTURE PROSPECTS 
  
The discovery of VEGFR3 as a LEC-specific marker in the mid 1990s was a 
groundbreaking finding that initiated a whole new era of lymphatic research. Yet the 
role of VEGFR3 in blood endothelia has remained elusive over the years, also 
because of the early embryonic lethality observed in VEGFR3 null mice. However, it 
has become clear that VEGFR3 signaling is essential in angiogenic conditions in 
physiological and pathological settings, for example in solid tumors. 
In the present study, we explored the mechanisms of VEGFR3 signaling in 
sprouting angiogenesis and elucidated a plethora of novel functions for this receptor. 
We identified VEGFR3 as a novel tip cell marker and a novel regulator of sprouting 
angiogenesis that possesses ligand-dependent and ligand-independent signaling 
properties in the blood vascular endothelium, and we clarified some of the signaling 
relationships of VEGFR3 to VEGFR2 and Notch pathways. Our findings highlight 
the importance of VEGFR3 signaling in tumor angiogenesis, since we showed that 
VEGFR3 collaborates with VEGFR2 in the formation of new vessels and is able to 
sustain angiogenesis even in the presence of VEGFR2 blockers; thus providing a 
signaling gateway for tumors in which VEGF inhibitors are used to block 
angiogenesis. 
Although our results improved our understanding on how VEGFR3 
contributes to blood vessel development and growth, several more questions remain 
to be addressed: To which extent does the VEGFR3/Notch signaling output depend 
on the endothelial cell microenvironment? Why interference with different 
components of the Notch signaling cascade results in different phenotypes in mice 
and zebrafish, and how could these results be translated clinically? How could we 
maximize the precision of genetic manipulation of mouse models and the 
interpretation of the experimental results? Would VEGFR3 inhibition in humans be 
effective in all tumor types? What would be the determinants of responsiveness to 
anti-VEGFR3 treatment and how could combinational strategies maximize the 
clinical benefit? Could VEGFR3 blockade provide dual inhibition of tumor 
angiogenesis and lymph node metastasis in cancer patients? Finally, since VEGFR3 
is expressed in angiogenic endothelia in the adult, it would be exciting to use the 
models established in these studies in order to investigate the contribution of 
VEGFR3 in other angiogenesis-related diseases, such as cardiovascular and 
inflammatory disorders. 
More than 40 years ago it was suggested for the first time that angiogenesis 
supports tumor growth. On the other hand, more recently, a series of significant 
discoveries have established the importance of the lymphatic system in human 
physiology, introducing a new exciting research area to the scientific community. 
During the past years a tremendous amount of work has significantly increased our 
knowledge and expanded the field of vascular biology into several directions. The 
challenge for the future would be to further comprehend the molecular mechanisms 
underlying angiogenesis and lymphangiogenesis, and develop more efficient 
therapeutic strategies to target these processes in human diseases. 
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